The Genetic Basis of Resistance to Transplantation Tolerance Induced by Costimulation Blockade in NOD Mice: a Dissertation by Pearson, Todd
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2003-03-17 
The Genetic Basis of Resistance to Transplantation Tolerance 
Induced by Costimulation Blockade in NOD Mice: a Dissertation 
Todd Pearson 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Animal Experimentation and Research Commons, Endocrine System Diseases Commons, 
Genetic Phenomena Commons, Immune System Diseases Commons, Nutritional and Metabolic Diseases 
Commons, Surgical Procedures, Operative Commons, and the Therapeutics Commons 
Repository Citation 
Pearson T. (2003). The Genetic Basis of Resistance to Transplantation Tolerance Induced by 
Costimulation Blockade in NOD Mice: a Dissertation. GSBS Dissertations and Theses. https://doi.org/
10.13028/wdt4-c315. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/16 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 
Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
THE GENETIC BASIS OF RESISTANCE TO TRANSPLANTATION TOLERANCE
INDUCED BY COSTIMULA TION BLOCKADE IN NOD MICE
A Dissertation Presented
Todd Pearson
Submitted to the Faculty of the
University of Massachusetts Graduate School of Biomedical Sciences, Worcester
in partial fulfillment of the requirements for the degree of
DOCTOR OF PHILOSOPHY
March 17, 2003
Program in Immunology and Virology
qp'
COPYRIGHT INFORMATON
The chapters of this dissertation have appeared in the following publications:
Pearson, T. , Markees, T. , Wicker, L.S. , Serreze, D. , Peterson, L.B. , Mordes, J.
Rossini , A.A. , and Greiner, D.L. 2003. NOD congenic mice genetically protected from
autoimmune diabetes remain resistant to transplantation tolerance induction. Diabetes
52: 321-326.
Pearson, T. , Markees, T.G. , Serreze, D. , Pierce, M. , Wicker, L.S. , Peterson, L.B.
Shultz, L.D. , Mordes, J.P. , Rossini, A. , and Greiner, D.L. 2003. Islet cell
autoimmunity and transplantation tolerance: two distinct mechanisms? Annals NY Acad
Sci USA. In press.
Pearson, T. , Markees, T. , Serreze, D. , Pierce, M. , Wicker, L.S. , Peterson, L.B.
Shultz, L.D. , Mordes, J.P. , Rossini, A. , and Greiner, D.L. 2003. Genetic separation of
the transplantation tolerance and autoimmune phenotypes in NOD mice. Rev Endo Met
Disorders. In press.
Pearson, T. , Markees, T. , Serreze, D. , Pierce, M. , Marron, M. , Wicker, L.S.
Peterson, L.B. , Shultz, L.D. , Mordes, J.P. , Rossini, A. , and Greiner, D.L. 2003.
Genetic disassociation of autoimmunity and resistance to co stimulation blockade-induced
transplantation tolerance in NOD mice. J. Immunol. In press.
qp'
THE GENETIC BASIS OF RESISTANCE TO TRANSPLANTATION TOLERANCE
INDUCED BY COSTIMULATION BLOCKADE IN NOD MICE
A Dissertation Presented
By
Todd Pearson
Dr. Dale Greiner, Dissertation Mentor
Dr. Anthony Carruthers, Dean of the
Graduate School of Biomedical Sciences
Program in Immunology and Virology
March 17, 2003
Approved as to style and content by:
Dr. Raymond Welsh, Chair of Committee
Dr. Leslie Berg, Member of Committee
Dr. Laurence Peterson, Member of Committee
Dr. David Serreze, Member of Committee
Dr. Aldo A. Rossini, Member of Committee
iii
ACKNOWLEDGEMENTS
I would like to thank my primary mentor, Dr. Dale Greiner and as well as Drs.
Aldo Rossini and John Mordes for allowing me to carry out this research in their
laboratory and affording me the opportunity to collaborate and interact with many
exceptional scientists. Additionally, I am especially grateful to Dale and Dr. Dave
Serreze whom gave me the option to pursue a thesis project at The Jackson Laboratory
and then handled the transition of a wayward graduate student back to UMass Medical
School. Dave has been open to my return trips to his laboratory to learn new techniques
devoted resources to my project and traveled down to Worcester for numerous committee
meetings all for my benefit. I am very appreciative for everyhing that Dave has done
To my committee members, Drs. Leslie Berg, Larr Peterson, Aldo Rossini, Dave
Serreze and Ray Welsh, thank you for your advice throughout my thesis project. It has
been a pleasure for me to learn from all of you.
There are many individuals in the Diabetes Division that have provided help
along the way: administrative staff, research assistants, graduate students , post-docs and
faculty. I could fill many pages thanking all of you.
My whole family, and in particular, my parents have been the driving force of
reaching this goal. Words cannot express how much their love and support means to me.
Finally, a very special thank you to my soon-to-be wife, Annie, who has made the last
two years the best of my life. You have been there for the everyday highs and lows of
graduate school and your love has been unwavering.
ABSTRACT
The NOD mouse is a widely studied model of type 1 diabetes. The loss of self-
tolerance leading to autoimmune diabetes in NOD mice involves at least 27 genetic loci.
Curing type 1 diabetes in mice and humans by islet transplantation requires overcoming
both allorejection and recurrent autoimmunity. This has been achieved with systemic
immunosuppression, but tolerance induction would be preferable. In addition to their
genetic defects in self-tolerance, NOD mice resist peripheral transplantation tolerance
induced by costimulation blockade using donor-specific transfusion and anti-CD 154
antibody. Failure has been attributed to the underlying autoimmunity, assuming that
autoimmunity and resistance to transplantation tolerance have a common basis.
Hypothesizing that these two abnormalities might be related, we investigated whether
they had a common genetic basis. Diabetes-resistant NOD and C57BL/6 stocks con genic
for various reciprocally introduced Idd loci were assessed for their ability to be tolerized.
Surprisingly, in NOD congenic mice that are almost completely protected from diabetes
costimulation blockade failed to prolong skin allograft survival. In reciprocal C57BL/6
congenic mice with NOD-derived Idd loci, skin allograft survival was readily prolonged
by costimulation blockade. Unexpectedly, we observed that (NOD x C57BL/6)Fl mice
which have no diabetes , nonetheless resist induction of tolerance to skin allografts.
Further analyses revealed that the Fl mice shared the dendritic cell maturation defects
and abnormal CD4+ T cell responses of the NOD but had lost its defects in macrophage
maturation and NK cell activity. Finally, using a genome wide scan approach, we have
identified four suggestive markers in the mouse genome that control the survival of skin
allografts following DST and anti-CD154 mAb therapy. We suggest that mechanisms
controlling autoimmunity and transplantation tolerance in NOD mice are not completely
overlapping and are potentially distinct, or that the genetic threshold for normalizing the
transplantation tolerance defect is higher than that for preventing autoimmune diabetes.
We conclude that resistance to allograft tolerance induction in the NOD mouse is not a
direct consequence of overt autoimmunity and that autoimmunity and resistance to
co stimulation blockade-induced transplantation tolerance phenotypes in NOD mice are
not under identical genetic control.
qp'
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INTRODUCTION
Overview of diabetes melltus
Diabetes melltus comprises a group of disorders characterized by hyperglycemia
and afflcts 14 milion Americans, with 800 000 diagnosed new cases each year (1). Most
cases are classified as type 1 or type 2 (2). Both types can cause debilitating symptoms
predispose to infection, complicate pregnancy, and lead to many secondary
complications. Indeed, diabetes is a leading cause of blindness and amputation in the
United States. Type 2 diabetes is the more common syndrome, accounting for
approximately 85% of cases. It is associated with obesity and generally occurs in adults
but can often be controlled by diet and exercise. Individuals with type 2 diabetes sQffer
,.'
from insulin resistance or a relative deficiency in insulin, meaning that insulin secretion is
altered, but not totally lost. Type 1 diabetes is less common, accounting for about 10% of
cases. It is an autoimmune disease caused by T cell mediated destruction of pancreatic
beta cells, resulting in an absolute insulin deficiency. In contrast to type 2 diabetes, type 
occurs most commonly during childhood. Patients with type 1 diabetes require exogenous
insulin for survival, but insulin therapy never achieves perfect glucose regulation, and
secondary complications of diabetes inevitably develop. The only currently available
alternative is transplantation of replacement beta cells, which would be curative.
Segmental pancreas transplantation can achieve normal glucose regulation and
insulin independence , but requires major surgery and immunosuppression and has a
substantial rate of post-surgical complications (3). Transplantation of islets isolated from
the pancreas would clearly be preferable because it is much less invasive. Successful islet
qp'
transplantation for type 1 diabetes was first reported in 1990 (4), but until recently
success rates were very low.
In 2000, however, researchers in Edmonton, Canada demonstrated that
transplantation of islets using a new regimen of islet preparation and immunosuppression
could cure type 1 diabetes with a success rate that appeared to rival that of segmental
pancreas transplantation (5 6). Promising results for more than 30 patients were reported
at the 2002 meeting of the American Diabetes Association, and two patients have
received transplants using this protocol at the University of Massachusetts Medical
School.
These successes have been encouraging, but islet transplantation to cure type 
diabetes continues to require immunosuppressive drugs. These are medications with both
detrimental side effects and potential long-term health risks. Although allograft recipients
! '
comprise a uniquely motivated group of patients, overall medication non-compliance
rates reportedly vary from 20 to 50% (7). In addition, many of these drugs have
deleterious effects on the function of beta cells (8). New formulations and treatment
schedules have made immunosuppression safer and more effective than in the past, but
diabetic patients considering pancreas or islet transplantation are stil forced to choose
between the risks of hyperglycemia and its complications on the one hand, and the risks
and side effects of lifelong systemic immunosuppression on the other. Because of the
risks, transplantation to ameliorate diabetes is primarily reserved for patients who have
extremely labile glycemic control and severe recurrent hypoglycemia, or who have renal
failure and need a kidney transplant. To make islet transplantation safe and more
acceptable, research in transplantation is focused on developing alternatives to
immunosuppression, most notably the induction of transplantation tolerance (9).
Rationale for small animal models
The pathology and genetic basis of type 1 diabetes in humans have been studied
extensively, but understanding of type 1 diabetes remains incomplete. The disease is
under polygenic control and penetrance is modified by environmental factors; identifying
at risk individuals is diffcult (10). In addition, studying disease in humans in general and
children in particular poses serious ethical limitations , especially when considering a
therapeutic intervention like an experimental transplantation procedure. Fortunately,
reliable animal model systems are available that allow us to analyze the pathogenesis of
autoimmune diabetes (11), the induction oftransplantation tolerance (9), and the special
problem of tolerance induction in the setting of autoimmunity (12).
Islet transplantation into autoimmune diabetics represents a unique situation
because two obstacles must be overcome: the induction of tolerance to a foreign tissue
and the prevention of autoimmune recurrence that is the cause for the transplant in the
first place. Autoimmune recurrence has been elegantly demonstrated by syngeneic
segmental pancreas transplantation between monozygotic twins discordant for diabetes, a
situation where immunosuppressive drugs are not required. The graft fails in the absence
of an alloimmune response because of a preexisting autoimmune condition in the
recipient (13- 15). Successes that have been seen with current pancreas and islet
transplantation protocols are likely due to the fact that the immunosuppressive regimens
that block the alloimmune response also inhibit the autoimmune process (9).
Central and peripheral transplantation tolerance
Tolerance in the immune system can be generically described as unresponsiveness
to antigen. T cell tolerance is accomplished by many mechanisms , but is most broadly
divided into two categories: central tolerance and peripheral tolerance (16). In the field
of transplantation, there are various definitions of what it means to be "tolerant."
Immunological" transplantation tolerance refers to the complete absence of an immune
response to the foreign tissue in the absence of immunosuppression. "Functional"
transplantation tolerance , a more clinically relevant definition, refers to the survival of a
foreign tissue in the absence of immunosuppression (9). Throughout this dissertation, we
wil use the "functional" definition of transplantation tolerance.
Central tolerance refers to tolerance that develops in the thymus during T cell
development (17). The main process that leads to central tolerance is clonal deletion.
Deletion removes immature thymocytes based on the strength of their TCR interaction
with a cognate MHC/peptide complex. Self-reactive cells that have a high avidity for self
MHC/peptide complexes are deleted intrathymically and don t enter the periphery (18).
There is also a non-deletional central tolerance mechanism, called clonal inactivation that
allows self-reactive cells to escape the thymus, but they are antigen unresponsive or
clonally anergic. Central tolerance mechanisms have been exploited to induce
transplantation tolerance by introducing alloantigens into the thymus to eliminate
alloreactive thymocytes as they develop. This can be accomplished with intrathymic
injection of antigen, or as discussed later, the induction of hematopoietic chimerism.
qp'
In spite of central tolerance mechanisms, some self-reactive cells do escape into
the peripheral immune system (19, 20). Peripheral tolerance mechanisms are in place to
prevent these cells from becoming inappropriately activated. There are numerous
mechanisms believed to be involved, including anergy, suppression, clonal exhaustion
and immune deviation (21). Transplantation researchers use peripheral tolerance
mechanisms to induce the long term survival of foreign tissues. It is this type of
transplantation tolerance that is the focus of this disserttion.
Modeling costimulation blockade-based transplantation tolerance
The transplantation of pancreata (3) and islets (22) using immunosuppression are
clinical procedures that were prototyped in animals. Development of transplantation
strategies that do not require immunosuppression is similarly based on animal
experimentation. Findings that translate reproducibly from animals to humans are based
on a detailed understanding of the underlying mechanisms responsible for immune
responses (23).
Several transplantation tolerance protocols prolong allograft survival in normal
inbred strains of mice (9). The strategies typically involve blockade of 1) TCR-
MHC/peptide interaction, 2) co stimulatory CD40-CD154 interaction, or 3) CD80/86-
CD28 interaction. These protocols can be used either to prevent activation of alloreactive
peripheral T cells (peripheral tolerance) or to establish hematopoietic chimerism (central
tolerance) (9).
In our laboratory we have developed a two-element protocol that consists of a
single transfusion of donor spleen cells (a donor-specific transfusion or DST) and a brief
qp'
course of anti-CD 1 54 mAb to induce peripheral transplantation tolerance (9). Its design is
based on interference of normal T cell activation (Figure lA). We hypothesize that this
protocol operates through the following mechanism: 1) Donor-origin resting APCs first
engage the TCR of alloantigen-specific T cells. 2) Anti-CD 154 mAb then prevents ligand
engagement of CD40 on the resting APC , 3) thereby preventing the up-regulation of B7
costimulatory molecules , MHC class II , and cytokine production (Figure IB). This
protocol results in permanent islet and prolonged skin allograft survival in normal mouse
strains (9) and non-human primates (24). Additionally, this protocol can prolong rat skin
and islet xenograft survival in normal mouse strains (25). We have determined that the
mechanism of prolonged allograft survival requires the elimination of alloreactive CD8
T cells from the circulation in a CTLA-4 dependent manner, the presence of CD4+ T
cells, and the secretion ofIFNy but not IL-4 or IL- IO (26, 27).
qp'
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Legend to Figure 1: The three-step model of T cell activation and the proposed function
of anti-CD154 mAb in preventing full T cell activation to establish tolerance. Panel A:
Summary of T cell activation. The TCR on a T cell engages the MHC/peptide complex of
an APC (Step 1). This interaction induces the upregulation of CD154 on the T cell and
CD40-CD154 interactions result in activation of the APC (Step 2). When the APC is
activated, it upregulates the B7-family molecules CD80 and CD86, which provide the
co stimulatory signal to the T cell needed for its full activation (Step 3). Panel B:
Prevention of T cell activation by anti-CD154 mAb. TCR-MHC interaction stil takes
place (Step 1), but the anti-CD154 mAb blocks CD154-CD40 interaction, preventing full
activation of the APC (i.e. blocks Step 2). As a consequence of failure to achieve full
activation, the APC does not upregulate B7 molecules, preventing the delivery of
co stimulation to the T cell (no Step 3). Signaling through the TCR in the absence of
costimulation renders the T cell tolerant.
qp'
Modeling type 1 diabetes in rodents
The two most common small animal models of type 1 diabetes are the
BioBreeding (BB) rat and the Non-obese Diabetic (NOD) mouse (11). Both strains
develop an autoimmune, type 1 diabetes-like syndrome. The pathophysiology of
autoimmune diabetes in both strains has been well studied and has similarities and
differences to each other and to human type 1 diabetes (11). These comparisons have
been well documented in the literature and have prompted investigators to exercise
caution when applying conclusions from animal studies to the human syndrome (23 , 28).
We have chosen the NOD mouse to study the special case of transplantation
tolerance in the context of autoimmunity. First, the mouse genome in general and the
immunogenetics of the NOD mouse in particular are very well characterized. Second
the availability of knockout, transgenic and congenic strains of mice allows for in depth
analysis. Third, reagents such as recombinant cytokines and monoclonal antibodies are
more abundant for mice. Finally, our transplantation tolerance induction protocol has
been extensively characterized in mice.
The NOD mouse model of type 1 diabetes
The NOD mouse was derived from outbred Swiss mice in Japan during the
1970' s (29). Swiss mice are also the progenitors of other common inbred strains
including SJL and SWR (30). Researchers were originally screening brother x sister
matings of Swiss mice for lines that developed cataracts, and developed two sublines
both free of cataracts: one had high fasting blood glucose levels and a second "control"
strain with normal fasting blood glucose levels. These sublines were inbred , and
amazingly, a female in the "control" strain spontaneously developed an autoimmune
diabetes-like syndrome. The offspring of this female gave rise to the NOD inbred strain
of mice. The other sub line, originally designed to be the diabetic line, gave rise to the
nonobese nondiabetic (NON) strain (29 30).
Type 1 diabetes in the NOD mouse is characterized by the T cell mediated
destruction of insulin producing beta cells in the pancreas (11
, 31 , 32). The onset of
hyperglycemia is predated by infitration of mononuclear cells at 4 to 5 weeks of age; at
first peripheral to the islet (termed "peri- insulitis ) and followed by more invasive
infitration directly into the islet ("insulitis ). Prevalence of type 1 diabetes in NOD/Lt
mice is 90% in females and approximately 60% in males by 20 weeks of age (11 , 31
32). In addition to the presence of pathogenic autoreactive T cells (33), NOD mice harbor
additional immunological defects.
These defects include abnormal maturation of bone marrow-derived antigen
presenting cells (34), reduced natural kiler (NK) cell (35 , 36) and natural killer T (NKT)
cell numbers and function (37-40), a pathogenic role for B cells (41-43), the absence of
hemolytic complement (44), and defects in regulatory CD4 CD25+ T cells (45 , 46). Some
of these immunologic abnormalities , such as a defect in NKT cells are believed to be
important in the pathogenesis of human type 1 diabetes (47), although this has recently
been questioned (48), while a role for others, such as the absence of hemolytic
complement, isn t even associated with diabetes in the mouse (44). Of particular interest
is the observation that many of the cell defects associated with the pathogenesis of
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diabetes are in the same cell subsets that are important for the induction of transplantation
tolerance (Table 1).
Preventing and curing type 1 diabetes in NOD mice
Fundamentally, NOD mice have a defect in T cell self-tolerance that appears to be
a failure of both central and peripheral tolerance mechanisms. The failure to delete
autoreactive thymocytes during development in the thymus has been demonstrated in a
number of studies (49-51). Similarly, defects in peripheral T cells have been observed.
Activation induced cell death (AICD) induced by in vivo administration of superantigen
is a classic demonstration of peripheral CD4+ T cell tolerance (52, 53). NOD CD4+ T
cells initially expand , but fail to delete following superantigen treatment (42). Using a
model self-antigen and TCR transgenic mice , Sherman and .co-workers have
demonstrated that NOD CD8+ T cells are relatively resistant to the induction of tolerance
(54). T cell self-tolerance defects are likely to be controlled by both T cell intrinsic
effects (49) as well as defects in other immunological compartents (41 , 50). Therefore
preventing type 1 diabetes will require protocols that result in improved central and/or
peripheral tolerance, and wil need to target T cells both directly and indirectly. An
impressive nl,mber of strategies have been attempted.
Prevention of diabetes in NOD mice
There are numerous ( l 00) immunosupppressive and immunoregulatory
protocols that prevent the spontaneous development of diabetes in NOD mice (11
, 28
31). These include non-specific modulations such as elevated temperature or
overcrowded housing, or more specific interventions such as administration of exogenous
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cytokines. Caution must be taken with studies documenting protection from of NOD
mice from diabetes, as the intervention may not translate into an appropriate therapy in
humans (23). In many cases, the mechanisms by which these protocols prevent diabetes
are unknown, but various hypotheses have been put forward. These include the skewing
of cytokine polarization from a Thl to a Th2 phenotype (55), the induction of regulatory
T cells (Treg) (56) and the maturation of antigen presenting cells (50 , 57-59).
Prevention of autoimmune recurrence in NOD mice
Remarkably, the prevention of autoimmune recurrence in NOD mice has been
quite poor in spite of the numerous treatments that prevent the spontaneous onset of
diabetes. To date , only chronic administration of immunosuppressive drugs (60, 61),
treatment with anti-CD3 antibody (62), or the establishment of hematopoietic chimerism
(63) prevent both autoimmune recurrence and the rejection of foreign tissues.
Induction of central tolerance by establishment of hematopoietic
chimerism
The establishment of hematopoietic chimerism has the potential to both prevent
autoimmune diabetes and to establish tolerance to tissue allografts of the same donor type
as the bone marrow graft (9, 64). The mechanism of action is thought to involve the
elimination of auto reactive and/or alloreactive thymocytes during development (65 , 66).
Work by Serreze (32 , 67) and others (68) has demonstrated the powerful ability of a
protective MHC haplotype on bone marrow-derived antigen presenting cells in the
thymus to mediate the elimination of self-reactive T cells and to prevent the spontaneous
onset of type 1 diabetes in NOD mice. Similar results have been observed when
employing chimerism to establish transplantation tolerance. Seung et al. were able to
induce donor-derived chimerism with sublethal irradiation, a brief course of anti-CDl54
mAb and a single hematopoietic graft (63). This protocol in combination with an
allogeneic islet graft of the same donor strain can permanently reverse diabetes in both
chemically induced diabetic non-autoimmune prone strains and in spontaneously
autoimmune diabetic NOD mice. In related studies, Sykes and co-workers have
established allogeneic hematopoietic chimerism in autoimmune diabetic NOD mice with
depleting antibodies against CD4 , CD8 , Thy1.2 plus a blocking anti-CD154 mAb
followed by sublethal conditioning (69). To date, the establishment of allogeneic
hematopoietic chimerism is the most potent form of transplantation tolerance that can be
achieved.
A major goal for translating hematopoietic chimerism to the clinic is to develop
protocols that reduce or eliminate the need for host myeloablative conditioning. In animal
models , the most promising approaches to achieve this goal are based on the use 
costimulation blockade. Chronic administration of anti-CD154 mAb and repeated
hematopoietic cell injections is suffcient to establish mixed chimerism in non-
autoimmune prone strains (70). Although low levels of chimerism were obtained
recipients were able to maintain the long-term survival of matched allogeneic cardiac
grafts. More recently, researchers have developed a protocol for establishing mixed
allogeneic chimerism using a short course of anti-CD154 mAb in combination with
CTLA-4 Ig (to block the B7:CD28 costimulatory pathway) with a conditioning regimen
of busulfan (71). Another non-myeloablative protocol based on costimulation blockade
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uses a very high dose of bone marrow (65). However, to date, translation of these
protocols to the NOD mouse have not been reported. We speculate that this is the result
of the resistance of NOD mice to the induction of peripheral transplantation tolerance
(12 , 72), which we hypothesize is critical for the establishment of hematopoietic
chimerism using co stimulation blockade. Based on the work in NOD mice, future studies
using hematopoietic chimerism to prevent autoimmune recurrence and to induce
transplantation tolerance should take into account the MHC haplotype of the stem cell
donor. This wil be important in both the induction of donor-specific transplantation
tolerance as well as the engraftment of cells expressing protective class I and class II
molecules that eliminate autoreactive T cells and prevent diabetes recurrence (32, 67, 68).
Induction of peripheral tolerance in NOD mice
There are a number of approaches for the establishment of peripheral
transplantation tolerance that are successful in normal, non-autoimmune mice (9).
However, most of these approaches have failed when translated to the NOD mouse. We
have hypothesized that NOD mice have a generalized defect in their response to
transplantation tolerance induction. NOD mice reject both allogeneic islet and skin grafts
when treated with therapies that induce prolonged or even permanent survival in non-
autoimmune strains (12). The cellular basis for the resistance of NOD mice to
transplantation tolerance induction is thought to be a consequence of their autoimmunity.
As discussed below, there are multiple immune defects that may be involved in each of
these two phenotypes; autoimmunity and resistance to transplantation tolerance.
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Cellular mechanisms that mediate resistance to transplantation tolerance
and expression of autoimmunity in NOD mice
The current understanding of the resistance to transplantation tolerance induction
in NOD mice is that they are: 1) controlled by the same genetic pathways; 2) mediated
by the same cellular abnormalities, and/or; 3) a function of the ongoing autoimmune
condition (Figure 2). Unfortnately, there has been little evidence that supports or refutes
these assumptions because the resources necessary to resolve these issues have not been
available. These hypotheses seem attractive, because as highlighted in Table 1 and
Table 2 a number of genetic and cellular defects that could be important in the induction
of transplantation tolerance and susceptibility to type 1 diabetes appear to be shared.
Figure 2
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Legend to Figure 2: Schematic diagram depicting the contribution of genetic and
cellular defects to autoimmunity and resistance to transplantation tolerance in NOD mice.
Represented is the conventional view that the Idd loci are responsible for a set of cellular
immunological defects that cause both autoimmune diabetes and resistance to
transplantation tolerance. These cellular abnormalities with a single genetic origin could
cause transplantation tolerance resistance either directly or as a secondary consequence of
the expression of autoimmune diabetes.
The role of CD4+ T cells in autoimmune diabetes and transplantation
tolerance
MHC class II restricted CD4+ T cells , also known as "helper" T cells (Th) are
central to the generation of both humoral and cell-mediated adaptive immune responses
(73). This function is achieved through the expression of secreted cytokines as well as
cell surface co-stimulatory molecules. CD4+ T cells are the primary cell type that
expresses CD154 , the ligand for CD40, an important B cell and APC activation receptor
(74, 75). Cytokines secreted by CD4+ T cells control the type of immune response by
activating specific cell types. Classically, this response has been divided into two broad
categories: Thl and Th2 (76). A Thl cytokine profie is characterized by secretion of
IFNy, IL-2 and TNF- and primarily activates cell-mediated responses such as DTH and
CTL. A Th2 profie mediates humoral responses and activates eosinophils by secreting
IL- , IL-5 and IL- lO cytokines. The CD4+ T cell cytokine profie has been hypothesized
to be important in the immunopathogenesis of a number of diseases, including type I
diabetes (55).
Role in type diabetes in NOD mice
Pathogenic CD4+ T cells , restricted to the unique I- MHC class II molecule
have been shown to be important in disease progression in NOD mice. Indeed, CD4+ T
cells isolated from overtly diabetic NOD mice can adoptively transfer disease (77-80).
However, they are probably not the cell type that initiates disease in the intact NOD host
but develop at about the time of disease onset (11 , 81).
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Regulatory CD4 CD25+ T cells, a cell type important in the control of peripheral
self-tolerance, appear to be defective in NOD mice. Their role in the progression of the
autoimmune process was elegantly documented using a stock of NOD mice deficient in
both CD80 (B7. l) and CD86 (B7.2) (45). CD80/CD86 deficient NOD mice develop a
rapid and severe autoimmune condition and have a paucity of CD4 CD25+ T cells.
Additional evidence for the role of regulatory CD4 CD25+ T cells in autoimmunity has
come from studies using anti-CD3 antibody. Chatenoud and colleagues (62 82) used low
doses of anti-CD3 mAb to reverse spontaneous diabetes and autoimmune recurrence in
NOD mice. Herold et al. have treated recently diabetic humans with a humanized , non-
depleting anti-CD3 mAb (83). In these studies , treatment with anti-CD3 mAb
immediately after the diagnosis of type 1 diabetes is able to prolong the "honeymoon
period where patients revert into an insulin- independent state. Recent reports have begun
to shed light on the mechanism of action of anti-CD3 mAb in mice and humans. These
studies use newer, modified versions of non-mitogenic anti-CD3 antibodies that cause a
Th 1 to Th2 shift in cytokine production. This cytokine shift is believed to be protective
from diabetes and induce an immunoregulatory T cell population (84, 85).
Role in transplantation tolerance
CD4+ T cells are also important in the survival of allografts after transplantation
tolerance induction. CD4+ T cells can recognize alloantigens via two mechanisms: direct
recognition of the allo-MHC on the graft or indirect presentation of alloantigens captured
and processed by host APCs then subsequently presented in the context of self-MHC
class II molecules (9). Recognition of alloantigen by CD4+ T cells likely plays a role in
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targeting a graft for destruction or alternatively, maintaining tolerance to the tissue. In
support of a role for CD4+ T cells in allograft survival, depletion of CD4+ T cells during
the maintenance phase of allograft survival causes rapid rejection (26). Furthermore
mice genetically deficient in CD4+ T cells are completely resistant to co stimulation
blockade-based tolerance induction protocols (27). In a series of ex vivo studies
alloantigen tolerance induced by costimulatory blockade was maintained by CD4+CD25+
T cells (86). In a recent report, peripheral transplantation tolerance based 
co stimulation blockade was shown to be dependent on a population of CD4+CD25+ T
cells that regulated the activity of CD154- independent CD8+ T cells (87), It wil be
important to determine if defects in NOD CD4+ T cells also mediate their resistance to
transplantation tolerance. Experiments in this dissertation begin to address this point.
The role of CDS+ T cells in autoimmune diabetes and transplantation
tolerance
CD8+ T cells or cytotoxic T lymphocytes (CTL), are the cytolytic arm of an
adaptive cell-mediated immune response (73). They have the ability to directly lyse a
target cell based on recognition of peptides presented in the context of MHC class I
molecules. Upon receiving help from CD4+ T cells, naive CD8+ T cells are activated and
release perforin and granzymes , two types of cytotoxic granules that damage the cell
membrane leading to cytolysis. Additionally, CTLs express the membrane bound
molecule CD95 (Fas ligand), which can lead to target cell destruction via capsase-
induced apoptosis on CD90 (Fas)-expressing cells (88). An important quality of CD8+ T
cells is the generation of memory CTL after an immune challenge (89). Memory CTL
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have the ability to respond to their specific antigen in the absence of CD4+ T cell help
and rapidly mount a secondary immune response. CD8+ T cells are important in the
elimination of virus infected cells and tumor cells and are often a target to induce
immunity via vaccination (90).
Role in type diabetes in NOD mice
The importance of CD8+ T cells in the pathogenesis of type 1 diabetes was long
overlooked, in part because the NOD mouse expresses the common MHC class I
molecules K and D , in contrast to the rare MHC class II molecule I- (33). However
in an elegent series of experiments conducted by DiLorenzo and coworkers , it was
demonstrated that the earliest islet-infiltrating cells are CD8+ T cells and these cells are
required for all but the end stages of disease progression (81). More recently,
autoreactive CD8+ T cell clones have been described, many of which have a conserved
TCR Va chain gene rearangement (81 , 91-93). A number of these autoreactive CD8+ T
cell specificities can cause diabetes independent of CD4+ T cell help (94, 95).
Role in transplantation tolerance
CD8+ T cells are capable of rejecting an allograft by both cytotoxic granules and
FasL-mediated .mechanisms (9). Direct recognition of the allo-MHC expressed on the
transplanted tissue is probably the major mechanism by which CTLs target a graft for
destruction. As described below , elimination of all ore active CD8+ T cells from the
circulation appears to be a crucial step in establishing transplantation tolerance in a
number of costimulatory blockade protocols (26, 96, 97).
In the unique situation of islet transplantation into autoimmune diabetics, it is
unknown if both autoreactive and alloreactive CTLs will respond equally well to
tolerization strategies. Presumably, both types of CTLs must be targeted to cure type 
diabetes by this strategy.
The role of T cell death in autoimmune diabetes and transplantation
tolerance
Although the function of T cells in autoimmune diabetes and transplantation
tolerance induction was described above, special consideration should be paid to T cell
death. T cells undergo apoptosis at many stages of their life cycle. It is important for the
cessation of the immune response and the ability of T cells to respond appropriately to
death" signals is crucial for the proper regulation of immune homeostasis.
Role in type diabetes in NOD mice
Abnormal responses of peripheral T cells in NOD mice have been described and
implicated in the pathogenesis of type 1 diabetes. For example, resistance ofCD4+ T cells
in NOD mice to activation induced cell death (AICD) after superantigen treatment has
been demonstrated (42, 52, 53). Also , resistance to T cell apoptosis in NOD mice has
been attributed to disregulated Bcl-x expression and has been implicated in disease
pathogenesis (98). Not surprisingly, NOD mice with a ongoing, smoldering autoimmune
process have elevated levels ofIL- + T cells in their periphery, and these activated cells
are believed to be important in autoimmune diabetes (99). Therapies focused on
elimination of these activated T cells. A cytolytic IL-2/Fc fusion protein that selectively
targ ts activated T cells has been shown to block autoimmunity in NOD mice (100).
Similarly, a combination therapy of the immunosuppressive sirolimus plus the
administration ofIL-2 has been shown to induce apoptosis in NOD T cells, lead to a Thl
to Th2 cytokine profie shift, and most importantly, prevent spontaneous and recurrent
autoimmunity (60).
Role in transplantation tolerance
Strategies that induce autoreactive T cell death to restore self-tolerance have also
been applied to the induction of allo-specific tolerance (97). For example, therapies that
block signals necessary for apoptosis also prevent the induction of peripheral
transplantation tolerance (101 , 102). Also, our laboratory has shown a requirement for the
elimination from the periphery of both alloreactive CDS+ (26 , 96) and CD4+ T cells
(unpublished observations) in tolerance induced by DST plus anti-CD154 mAb
presumably by inducing apoptosisofthe activated alloreactive T cells.
The role of natural kiler and natural kiler T cells in autoimmune diabetes
and transplantation tolerance
Natural kiler (N) and natural kiler T (NT) cells are two related cell types that
bridge the innate and adaptive immune response. NK cells were originally described
based on their ability to lyse tumor and virus infected cells without prior activation or T
cell help (73). ' Their effector mechanisms are similar to CTLs, in that they utilize
perf orin and granzymes, but they do not express a TCR or CD3 complex. Instead, NK
cells express a complex set of receptors, both activating and inhibitory. The summation
of signals through these receptors determines whether or not an NK cell wil kill a target
cell (1 03). NK cells can also mediate antibody dependent cellular cytotoxicity (ADCC) of
antibody coated targets through the expression of Fc receptors on their cell surface.
Additionally, NK cells secrete IFNy during the early phase of an immune response
thereby activating T cells (104).
NKT cells share characteristics of both NK cells and T cells. They express a
number of NK cell surface proteins, but also express T cell membrane receptors
including the TCRlCD3 complex (73). A major subset of mouse NKT cells are restricted
to the non-classical MHC class I molecule, CD 1 d and have a heavily biased TCR
rearrangement (105). CDI molecules present gylcolipid antigens, and the marine
sponge-derived glycolipid a-galactosylceramide (aGaICer) that also binds CDI is a
strong NKT cell agonist. The effector functions of NKT cells are characterized by the
rapid secretion of thecytokines IL-4 and/or IFNy early in an immune response and this is
believed to be one mechanism by which the adaptive arm of the immune system is turned
on (106).
Role in type diabetes in NOD mice
NOD mice have deficiencies in NK cell number and function (35, 36, 107).
However, a role for NK abriormalities in the pathogenesis of diabetes in this strain has
been diffcult to determine, in part because NOD mice are NK1.l null at the NKRP-
complex, making the identification and analysis of both NK and NKT cells diffcult. The
congenic introgression of a resistance allele at Idd6 which harbors genes important in
NK and NKT cell function, including the NK1.1 allele at the NK- l complex, improves
NK and NKT cell function in NOD mice and renders them modestly protected from
diabetes (36).
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NKT cells have been hypothesized to be important in the pathogenesis of type 
diabetes in both humans (47) and NOD mice (37-40). As such, many investigators have
been attempting to determine the consequences of the NKT cell defect in NOD mice and
then develop strategies that improve function of this subset of cells. The importance of
NKT cells in the progression of autoimmune diabetes has been demonstrated by genetic
disruption of CD 1 in NOD mice, which results in the absence of CD I-restricted invariant
NKT cells (38 , 108). In these mice, an accelerated onset and increased prevalence of
disease is seen which is associated with an increase in the numbers of activated and
memory T cells. Understandably, a number of investigators have attempted to exploit the
function ofNKT cells in hopes of restoring self-tolerance and preventing the autoimmune
attck. Administration of the NKT cell receptor agonist aGalCer dramatically reduces the
spontaneous onset of diabetes in NOD mice to 10% to 40% (vs. 90% in untreated NOD
mice) (38, 109, 110). Furthermore, aGalCer treatment also reduces the severity of
insulitis and can prevent autoimmune recurrence in overtly diabetic mice given syngeneic
islet grafts. The mechanism of action of this treatment is not completely known, but a
shift to a Th2 type cytokine profie as well as an accumulation of NKT cells in the
pancreatic lymph nodes that regulate tolerogenic myeloid dendritic cells (57, 110 , 111)
have been implicated.
Role in transplantation tolerance
NK cells likely have only a minor role in the survival of tissue allografts in
tol rized recipients. NK cells participate in graft versus host disease (GVHD) (112) as
well as in the rejection of hematopoietic grafts (113). Interestingly, human NK cells
express CD154 and could be one target of treatment with DST and anti-CD154 mAb
(114).
A role for NKT cells in transplantation tolerance induction has also been
suggested. NKT cell deficient mice rapidly reject corneal allografts and this correlates
with an absence of regulatory NKT cells in the anterior chamber of the eye (115). Others
have demonstrated the importance of NKT cells in cardiac and skin allograft models
(116). Mice deficient in NKT cells are resistant to tolerance induced by anti-LFA- l plus
anti-B7. 1/2 mAbs, and this phenomenon was dependent on IFNy production by NKT
cells (117). It is currently uncertain if the defects in NK and NKT cells in NOD mice
mediate their underlying resistance to transplantation tolerance.
The role of B cells in autoimmune diabetes and transplantation tolerance
B cells are the effector cells of humoral immunity, secreting antibodies in
response to a variety of extracellular challenges (73). Activation of B cells occurs
through the B cell receptor (BCR), which consists of a membrane-bound immunoglobulin
associated with two Ig-a/lg- heterodimers. B cells express a co-receptor complex as
well as CD40, which help achieve full activation. Upon activation, B cells undergo class
switching and affinity maturation of immunoglobulin genes, resulting in high affnity,
antigen-specific antibody responses. Additionally, activated B cells express MHC class
II and B7 molecules and can function as antigen presenting cells to T cells, efficiently
presenting antigenic determinants that are specific for the BCR (118).
Role in type diabetes in NOD mice
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An important role of B cells in diabetes in NOD mice has been demonstrated. B
cell deficient NOD mice are completely protected from disease (41). Antibodies against
the putative diabetes autoantigens, GAD and insulin, can be detected in NOD mice, but
the importance of autoantibodies in diabetes pathogenesis is not well understood. One
pathogenic role of B cells that has been described is to function as antigen presenting
cells, specifically by capturing islet antigens via the BCR and subsequently presenting
antigenic determinants on MHC class II molecules (119).
Role in transplantation tolerance
Antibodies potentially can playa role in graft rejection. Natural antibodies in part
mediate hyperacute rejection of xenografts , while the generation of antibody responses
against allo-MHC antigens from prior blood transfusions or a previous allograft can
impact the outcome of a tissue transplant, perhaps by targeting it for ADCC (9).
With respect to the induction of transplantation tolerance, the role ofB cells is not
well understood. In our two element protocol, B cells are present in the DST and
presumably anti-CD154 mAb blocks the activation and subsequent upregulation of
costimulatory molecules on these cells. Others have reported that host B cells must be
tolerized to alloantigens and that administration of soluble antigen (120), anti-CD45
(121) and anti-CD154 mAbs (122, 123) can be used to achieve this.
The role of antigen presenting cells in autoimmune diabetes and
transplantation tolerance
Antigen presenting cells are mediators of self-tolerance and immunity (124).
They are not one specific cell , but rather a collection of cell types that function to activate
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effector T cell responses. Dendritic cells of both lymphoid and myeloid origin function
as "professional" APCs, but a number of other cell types, including macrophages and B
cells also have the ability to effciently activate T cell responses. The hallmarks of APC
function are the ability acquire antigen and then process and present it in the context of
MHC class I and class II molecules to T cells , while expressing costimulatory molecules
such as B7 family members to allow full T cell activation (73). Additionally, cytokine
secretion by APCs serves to further modulate T cell responses.
Role in type diabetes in NOD mice
NOD mice have well-documented abnormalities in various APC compartments
that are believed to be important in the expression of autoimmune diabetes (125).
Individual consideration was given to B cells above, while two other cell populations are
described below.
Defective maturation of NOD macrophages cultured from bone marrow
progenitors in the presence of CSF- l has been determined to be due to defective
regulation of the CSF- l receptor. Additionally, those macrophages that do mature
respond abnormally to mitogenic stimulation and produce low levels of IL- compared
to macrophages derived from other strains. Defective IL- secretion has been
implicated in the pathogenesis of autoimmune diabetes in NOD mice (126- 128).
Dendritic cells have been studied extensively in NOD-ice and vanous
abnormalities have been described ranging from impaired maturation (129, 130) to hyper-
activation (131 , 132). One defect observed from ex vivo isolated NOD dendritic cells is
low CD86 expression which is hypothesized to result in impaired self-tolerance due to a
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failure to upregulate CTLA-4 on CD4+ T cells (133). Furthermore, the adoptive transfer
of syngeneic freshly isolated DCs, peptide-pulsed DC, or in vitro cultured bone marrow-
derived CD86+ dendritic cells prevents diabetes in NOD mice. This protection is likely
due to the induction of a regulatory cell population (57 , 58, 134, 135). Similar to the
effects on DC maturation seen after administration of aGalCer, stimulation of NOD DC
ex vivo with IFNy before adoptive transfer results their accumulation in the pancreatic
lymph nodes and the prevention of diabetes (136).
Role in transplantation tolerance
An important role for APCs in the induction of transplantation tolerance may
seem obvious , but in the case of B cells (as mentioned earlier) and macrophages, the
relationship remains poorly understood. Mixed lymphocyte cultures carried out while
blocking B7/CD28 interactions results in the generation of macrophages that can
suppress T cell activation, implicating a potential tolerogenic role for macro phages in
tolerance induced by costimulatory blockade (137). In a study from our group, the NOD
macrophage maturation defect was shown to correlate with this strain s generalized
resistance to transplantation tolerance induction (12).
The use of "tolerogenic" dendritic cells is an appealing approach for the induction
of transplantation tolerance. Numerous transplantation protocols utilize anti-CD 1 54 mAb
an intervention believed to block the T cell dependent maturation of DC , rendering them
immature" or "tolerogenic." This phenomenon can be mimicked by co-culture ofT cells
with recipient-origin immature DC pulsed with allogeneic peptides , a system which
tolerizes T cells (138). Additionally, DC that have captured apoptotic debris are believed
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to be tolerogenic (139) and the injection of apoptotic cells improves the acceptance of
allogeneic bone marrow grafts
, presumably through the generation of tolerogenic DC
(140). Finally, others investigators have utilized gene 
therapy or other in vitro
manipulations to generate donor-derived DC expressing tolerogenic molecules such as
IL- , TGF , CTLA4 Ig or FasL to induce transplantation tolerance (141- 144).
The importance of considering the cellular mechanisms of 
autoimmune
diabetes and transplantation tolerance together
There are many cellular immune abnormalities that are important in the
progression of autoimmune diabetes in NOD mice. A number of these cell types are also
believed to be important in the induction of transplantation 
tolerance (Table 1). It is
interesting to speculate that the cellular defects that result in autoimmune diabetes in
NOD mice also render it resistant to transplantation tolerance induction. To investigate
this possibility, an understanding of the genetic basis of these two phenotypes must be
obtained.
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Table 1
Cell Subset Defects in NOD Mice Role in Transplantation
Tolerance
Effector CD4+ and CDS+ T Abnormal deletion of
cells activated T cells
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CD4+cCD25 ) regulatory T Abnormal function
cells
Deletion required for
transplantation tolerance
Required for transplantation
tolerance
NKT cells
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Defective cytokine
secretion and ability to
mature dendritic cells
Suggested to be important in
transplantation tolerance
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'M_"_'''_''-'-'''-'
-'''''-''- ' -''' _._...__. _ ._. _. . .._ .. .. _......._----_._.. _..
NK cells Defective, not required for
expression of diabetes
Role in transplantation
tolerance u
ruown
Dendritic Cells Abnormal maturation
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Tolerogenic dendritic cells
important in tolerance
induction, required for
induction of regulatory T
Macrophages Abnormal maturation
...._ _ ._ . .. .._.........._. ._. .._...... .._...__ _. ._ ... -_..._..._ .._..__ _ ._.. _. ...__.._.., .. _ ._ _ -. _. _. _.__ __ _.. _. _ . _... . -- .. .----.- - . .-. . --.- . ... .- . . ." -- .
cells
Role in transplantation
tolerance unknown
B Cells
_. _ . .. ._ . _ -. .._ ._ _ _ - __. _._.. _ .._ _. .. _.._. . __ _.... ."_ . . _._ . -_ _ ._ .. . ._ .._ _ ... . . _ ... ... _ . .- - . ... . --. . -... - . - -
Required as APCs for
expression of diabetes;
secrete autoantibodies
Suggested to be important in
transplantation tolerance
Legend to Table 1: Immune cells hypothesized to be importnt in the pathogenesis of
diabetes and in the induction of transplantation tolerance.
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Genetic basis of autoimmune diabetes in NOD mice and the induction 
transplantation tolerance
Idd loci and autoimmunity
The immunogenetics of autoimmune diabetes in NOD mice has revealed no fewer
than 27 diabetes susceptibility loci (termed Idd loci) on 15 chromosomes of the mouse
genome (11 32). The vast majority of diabetes susceptibility alleles are derived from the
NOD, but it is important to note that control strains harbor susceptibilty alleles and that
the NOD harbors some diabetes resistance loci (11). Many NOD Idd loci have human
orthologues, including the most powerful susceptibility loci in mice Iddl which maps to
the major histocompatibility Qomplex (MHC) (11 , 145). Indeed, NOD mice express a rare
MHC class II molecule, I- that is very similar to non-asp57 class II alleles that map to
IDDMI in humans (146- 148). Other non-MHC Idd susceptibility loci have been well
characterized and include candidate genes that are important in immune function (145).
Determining the actual pathogenic genes in a given locus has proven diffcult, and to
date
, P2 microglobulin (132m) is the only non-MHC gene that has been definitively shown
to confer diabetes susceptibility or resistance (149). Other candidate genes include Il2
(interleukin-2 gene), Cd152 (CTLA-4), Casp8 (caspase 8 gene), Ins- (insulin gene) and
others (145). Currently, identifying candidate genes is essentially a process of elimination
by continued narrowing of congenic intervals containing resistance alleles by extensive
backcrossing, with transgenic rescue or gene "knock- " technology providing the only
definitive proof of the function of the gene (150). The sequencing of the mouse genome
qp'
and wil aid in the identification of the actual diabetogenic genes and their products
within each Idd interval.
It is reasonable to think that genes in Idd intervals that mediate expression of
diabetes might also control the response to transplantation tolerance induction in NOD
mice. As summarized in Table 2 there are a number of candidate genes within Idd loci
that either have been shown to be or could be important in transplantation tolerance
induction.
The role of the genetic background on transplantation tolerance induction
Very few data are available on the potential effects that genetic background plays
in a strain s response to transplantation tolerance induction. Indeed , it is likely that an
examination across many inbred strains wil demonstrate varying responses to
co stimulation blockade transplantation tolerance induction. In agreement with this
Larsen, Pearson and co-workers have observed such a phenomenon (151). Their protocol
induces prolonged allograft survival by simultaneous blockade of CD40 and CD28
signaling. This treatment is effective in C3H1eJ recipients, but not C57BL/6 recipients.
U sing a series of recombinant inbred strains between C3H1eJ and C57BL/6 , they
observed a number of linked markers that associated with allograft survival in mice
treated with co stimulatory blockade.
The role of the MHC in tolerance induction
A genetic background effect that is likely to be important is the MHC haplotype
of the recipient and its interaction with the donor haplotype. The NOD haplotype is
neither necessary nor suffcient to result in resistance to transplantation tolerance (12),
but it seems possible that it may impact an animal' s response to tolerance induction.
Indeed, from the results of Markees and coworkers it can be conjectured that the 
haplotype diminishes the survival of allografts on C57BL/6. mice (i. e. 75 days vs
::100 for wild type C57BL/6). Furthermore, it has recently been shown that the
donor/recipient pairing is important in NOD recipients of full and partial MHC
mismatched grafts. When transplanting cardiac allografts, better matching of the donor
MHC improves survival in NOD recipients. However, when transplanting islets (i.e. the
target of the autoimmune attack), better matching of the donor MHC actually worsened
graft survival, likely because of autoimmune recurrence in addition to the allospecific
response (152).
Table 2
Locus Candidate Genes Candidate Genes in Transplantation
Tolerance
Idd1 MHC class II and class I genes Unkown; may confer resistance
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Table 2: Partial list of Idd loci, candidate genes within th6 Idd loci, and their relationship,
ifknown, in transplantation tolerance.
Thesis goals and specific aims
The NOD mouse continues to be the model of choice for developing therapies to
cure type 1 diabetes , including islet transplantation. However, the basis for this strain
resistance to co stimulation blockade-based transplantation tolerance induction protocols
remains elusive. Determining if this resistance is unique to NOD mice or alternatively
represents a condition that might be found in human type 1 diabetics has important
consequences for the study of transplantation tolerance in this mouse model of
autoimmune diabetes. To better understand this problem, three specific aims were
addressed:
Specifc aim 1: Tests the hypothesis that the genetic loci that mediate expression of
diabetes also control resistance to transplantation tolerance in NOD mice. Chapter I is
comprised of the data testing this hypothesis.
Specifc aim 2: Hypothesizes that increasing the "threshold" of self-tolerance wil
improve the response to transplantation induction in (NOD x C57BL/6)Fl mice. The
results of experiments exploring this hypothesis are presented in Chapter II.
Specifc aim 3: To identify the genetic intervals mediating resistance to tranpslantation
tolerance in NOD mice. The approach for this aim is a backcross genome wide scan
using quantitative trait linkage (QTL) analysis to identify loci that control skin allograft
survival on mice treated with DST and anti-CD154 mAb. The data are presented in
Chapter II.
It should be pointed out in advance that the majority of transplantation
experiments reported in this dissertation are skin grafts. This is done for both practical
qp'
and scientific reasons. In a practical sense, skin grafting is less costly, less labor
intensive and graft survival is easier to monitor. Scientifically, skin is considered to be
the most stringent test of allotolerance, because of its potent immunogenicity. Therefore
if a tolerance induction protocol can achieve prolonged skin allograft survival, it is likely
that other transplanted tissues wil succeed with the same protocol.
METHODS
Animals
C57BL/6 (H2
), 
C3H1eJ (H2
), 
and BALB/c (H2 mice were obtained from the
National Cancer Institute (Frederick, MD). NOD/MrkTacfBR, NOD.B6 Idd3R450
NOD. BlO Idd5R444 NOD.B6 Idd3R450 BlO Idd5R8 NOD.BlO Idd9R28 NOD.
IddlOIdd18R2 NOD.B6 Idd3IddlOIdd18R323 (all and C57BL/6NTac (H2 were
obtained from Taconic Farms (Germantown, NY). NOD/Lt (H2 mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). C57BL/6.NODc1c, C57BL/6.NODclt
C57BL/6.NODc3 and C57BL/6.NODc6 mice (H2 developed by Edward Wakeland
University of Texas Southwestern Medical Center, Dallas, TX) were the gift of Dr.
Edward Leiter (The Jackson Laboratory, Bar Harbor, ME). C57BL/6.NODc17 mice
(H2 developed by Edward Wakeland) were the gift of Dr. David Serreze (The Jackson
Laboratory, Bar Harbor, ME) and are hereafter referred to as C57BL/6. Table 3
summarizes the congenic interval(s) and diabetes incidence of each of the congenic
mouse strains listed above that were used in these experiments. BlO.D2-HcO (genetic
designation: BlO.D2- H2-TUf Hc SnJ) and BlOD2- mice (genetic designation:
BlO.D2- H2-TUf Hc /nSnJ) were obtained from The Jackson Laboratory.
C57BL/6.CD8a l- (H2 offcial designation: C57BL/6. l29S2-Cd8dmIMak were obtained
from The Jackson Laboratory (Bar Harbor, ME). NOD.CD8a l- mice (H2 official
designation: NOD. 29S2(B6)-Cd8atmIMakIDVS) were the gift of Dr. David Serreze. This
stock has the CD8a l- mutation introduced by congenic transfer and have been
backcrossed to the N9 generation. NOD.CD8a l- mice are homozygous for linkage
markers delineating all known Idd loci of NOD origin and are very strongly protected
from diabetes (1/17 females diabetic by 30 weeks of age).
To generate first filial (Fl) generation progeny, a single outcross was performed
and the resulting hybrids are designated with standard nomenclature: (mother x father)Fl.
The Fl progeny used in these studies include: (NOD x C57BL/6)Fl , (C57BL/6 x
NOD)Fl and (NOD.CD8a l- C57BL/6. CD8a )Fl (all H 2g7xb
); 
(NOD x
C57BL/6. )Fl (NOD. B6 Idd3 R450 BlO Idd5 R8 x C57BL/6. )Fl and
(NOD.BlO Idd9 R28 x C57BL/6. )Fl (All 
). 
To generate N2 generation animals
homozygous for the H 2 haplotype (NOD x C57BL/6.H 2 )F 1 females were
backcrossed to a C57BL/6. male and the resulting progeny are designated (NOD x
C57BL/6. )Fl X C57BL/6. (H2
All animals were certified to be free of Sendai virus , pneumonia virus of mice
murine hepatitis virus, minute virus of mice, ectromelia, LDH elevating virus, mouse
poliovirus, Reo-3 virus, mouse adenovirus, lymphocytic choriomeningitis virus
polyoma Mycoplasma pulmonis and Encephaliozoon cuniculi. They were housed in a
specific pathogen free facilty in microisolator cages , and given autoclaved food and
acidified water ad libitum. All animal use was in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC) of the University of
Massachusetts Medical School and recommendations in the Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory Animal Resources , National Research
Council, National Academy of Sciences, 1996).
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Legend to Table 3: Congenid strains, chromosomal location, frequency of diabetes and
insulitis and candidate genes in each interval. The specific genetic intervals and a more
complete listing of candidate genes contained within each interval can be found in (153-
157) IPercent of females scoring positive for moderate (10% to 50% of islets positive for
lympocytic infitrate) to severe (::50% islets positive for lymphocytic infitrate) insulitis
at 6-8 months of age, 2Diabetes prevalence in females at seven months of age.
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Tolerance induction and in or islet allograft transplantation
Graft recipient mice were treated with DST and anti-CD154 mAb and
transplanted with skin or islet allografts as described (27). Briefly, the DST consisted of a
single intravenous injection of 10 C3H/HeJ or BALB/c female spleen cells obtained
from 5 to 10 week old donors. The DST was injected on day -7 relative to skin
transplantation. Clone MRI hamster anti-mouse CD154 mAb (158) was produced as
ascites in scid mice and purified by Protein A affinity chromatography (Amersham
Pharmacia Biotech AB , Uppsala, Sweden). Antibody concentration was determined by
measurement of optical density and confirmed by ELISA as described previously (26).
The concentration of contaminating endotoxin was determined commercially (Charles
River Endosafe, Charleston, SC) and was uniformly -010 units EU per mg ofmAb. Mice
were injected intraperitoneally with anti-CD154 mAb (0.25 or 0.5 mg/dose as indicated
in text) on days - , -4 , 0 , and +4 relative to skin transplantation. Full thickness skin
grafts 1-2 cm in diameter were obtained from the flanks of donor mice and transplanted
onto the dorsal flanks of recipients as described (27). Grafts were examined 3 times
weekly, and rejection was defined as the first day on which the entire graft surface
appeared necrotic (27). Grafts adherent to the bandage or fully necrotic on day 7 were
deemed technical failures and were excluded from analysis (27) .
Islets were isolated by collagenase digestion followed by density gradient
separation as described (12 , 63). Handpicked islets (20 islets/gram body weight) were
transplanted into the renal subcapsular space of recipients.
qp'..::,
Diabetes was induced in male mice by a single intraperitoneal injection of
streptozotocin (150 mg/kg). Hyperglycemia was verified by 2 consecutive days of plasma
glucose levels ?250 mg/dL (Glucose Analyzer 2, Beckman Instruments , Fullerton, CA).
Diabetes was induced at least one week before initiating the tolerance induction and
transplantation procedures. Rejection of functional islet allografts was monitored by
plasma glucose and defined as a return to hyperglycemia (?250 mg/dL) on at least 2
consecutive days.
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Legend to Figure 3: Sch matic diagram of transplantation tolerance induction with DST
and anti-CD154 mAb. Recipient mice receive a DST consisting of lxl07 donor
splenocytes intravenously on day -7 relative to transplantation as well as four
intraperitoneal injections of 0. 5 mg of anti-CD154 mAb on days -
, -
, 0 and +4 relative
to transplantation. A skin allograft is placed on the recipients dorsal flank on day 0, the
day of transplantation. After surgery, recipients are monitored periodically for graft
survival. Rejection is defined as the first day that the entire graft appears necrotic.
Serum levels of hamste anti-CD154 mAb
Clearance kinetics of the anti-CD 1 54 mAb was determined in groups of NOD and
C57BL/6 mice that were given a single intraperitoneal injection of 2.0 mg of antibody.
Serum was collected from blood obtained prior to antibody injection and periodically
thereafter, up to 40 days after injection. Hamster IgG levels were quantified in the serum
samples by ELISA (26).
Flow cytometry
Purified rabbit anti-asialo GM- l polyclonal antibody was obtained from Wako
Chemicals USA (Richmond, VA). FITC-conjugated goat anti-rabbit Ig polyclonal
antibody obtained from BD PharMingen (San Diego, CA) was used to visualize cell
bound anti-asialo GM-l antibody. Biotinylated anti-mouse pan-NK cell mAb (clone
DX5), FITC-conjugated anti-NKR-PlC mAb (clone PK136), PerCept -conjugated anti-
CD3E mAb (clone l45-2Cll), PE conjugated anti-CD25 mAb (clone PC6l), PerCept
conjugated anti-CD4 mAb (clone RM4-5), FITC-conjugated anti-CD86 mAb (clone
GLl), APC-conjugated anti-CDllb mAb (clone Ml/70) and PE-conjugated anti-CDllc
mAb (clone HL3) were obtained from BD PharMingen. APC-conjugated streptavidin
was used to visualize bound DX5 as well as any bound biotinylated rat IgM, K (clone R4-
22) isotype control. Additional isotype controls included PerCept -conjugated hamster
IgGJ, K (clone A19-3), FITC-conjugated mouse IgG , K (clone G155- l78), PE-
conjugated rat IgM, K (clone R4-22), PerCept -conjugated rat IgG2a, K (clone R35-95),
FITC-conjugated rat IgG2a, A (clone B39-4), APC-conjugated rat IgG2b, K (clone A95-
and PE-conjugated hamsier IgG 1 , A (clone G235-2356). All isotype controls were
obtained from BD PharMingen.
Two and three color flow cytometry analyses of freshly isolated spleen cells or
cultured dendritic cells were performed as previously described (96). Briefly, 1 x 10
viable cells were first incubated for 5 min at 4 C with anti-FcyRIII/II mAb (clone 2.4G2)
to eliminate non-specific Fc binding of conjugated antibodies. Cells were then washed
and reacted with a mixture of conjugated mAbs for 20 min. In some cases, a third
incubation with APC-conjugated streptavidin or FITC-conjugated goat anti-rabbitt Ig was
performed. Stained cells were washed, suspended in 1 % paraformaldehyde-PBS , and
analyzed using a F ACScan flow cytometer (Becton Dickinson, San Jose, CA). Viable
lymphoid cells were gated according their light-scattering properties , and approximately
5 to 5.0 x 10 events were acquired for each analysis.
Natural kiler cell cytotoxicity assay
Cytotoxic activity ofNK splenic cells was quantified using a previously described
Cr-release micro cytotoxicity assay (111). NK-sensitive Y AC- l virus- induced mouse T
cell lymphoma (159) target cells were obtained from the American Type Culture
Collection (A TCC , Manassas, V A) and maintained in our laboratory in RPMI media
(Gibco Life Technologies, Gaithersburg, MD) supplemented with 10% Fetal Clone serum
(FC, HyClone, Logan, Utah). Y AC- l target cells in growth phase were labeled with SI
as sodium chromate (100 Ci/milion cells, New England Nuclear, Boston, MA), and
Cr-labeled cells (1.0 x 10 ) were added to each well of a 96 well microtiter plate.
Freshly isolated spleen cells obtained from animals injected intraperitoneally with 1 00 
qp'
poly I:C 24 hours earlier were added at effector to target (E:T) cell ratios ranging from
100 , 50 25 and 12.5:1 and incubated for 4 hours at 37 C in a humidified atmosphere of
95% air-5% C02 (160).
Total releasable radioactivity ("Cpmmaximat) was determined by incubating an
aliquot of Cr-labeled target cells with 5% Triton X-lOO. After incubation, cells were
pelleted by centrifugation, and 100 !-l aliquots of supernatant were transferred to a
separate microtiter plate containing 100 !-l Optiphase Supermix -scintilation fluid
(Wallac, Inc. Gaithersburg, MD) and counted ("cpmtest" using a 1450 Microbeta Trilux
instrument (W allac). Spontaneous release was uniformly -015% of maximal release. All
assays were performed in triplicate and averaged and each assay was performed at least
twice. Specific cytotoxicity was calculated as a percentage using the raw counts per
minute (cpm) and the formula:
test spontaeous
peCI IC YSIS /0 = 
cpmmaxal - cpm spontaeous
Macrophage IL-1 P production assay
Bone marrow-derived macrophages were generated as previously described (128).
Briefly, 5 x 10 bone marrow cells were cultured for 4 days at 37 C in RPMI- lO% FC
plus 500 U/ml human CSF- l (Sigma, St. Louis, MO) and 10 U/ml rat IFNy (R & D
Systems , Minneapolis, MN). The cells were cultured an additional 16 hours in fresh
media containing 10 !-g/ml bacterial lipopolysaccharide (LPS , Sigma, St. Louis , MO) in
the absence of additional growth factors. Supernatants were harvested and levels of
qp'
biologically active IL- were quantified in a C3H/eJ thymocyte co-mitogenic assay as
described (128). Data are presented as mean cpm of eH)Thymidine incorporation.
Dendritic cell maturation assay
Bone marrow was flushed from the femurs and tibias of euthanized donors into
RPMI- lO% FC serum. Erthyrocytes were lysed with 0.85% hypotonic NlICllysis buffer
and the mononuclear cells were washed twice more in RPMI- I0% FC. Viable
mononuclear cells were counted and suspended at 2 x 10 cells/ml in RPMI- lO% FC
supplemented with 500 U/ml recombinant mouse GM-CSF and 1000 U/ml recombinant
mouse IL-4 (R & D Systems). Bone marrow cells (3 x 10 ) were cultured in a six well
tissue culture plate in a total volume of 3 ml/well. Typically, the cultures for each strain
consisted of pooled bone marrow from two mice. Cultures were incubated at 37 C in an
atmosphere of 95% air 5% C02. On day two , non-adherent cells were removed by gentle
swirling and half the medium was replaced with fresh medium supplemented with 500
U/ml GM-CSF and 1000 U/ml IL-4. On day four, non-adherent cells were removed and
fresh medium supplemented with cytokines was added as on day two and 5 g/ml of an
agonist anti-CD40 mAb (clone HM40- , BD PharMingen) was added to the appropriate
wells. Cultures were incubated an additional 48 or 96 hours. After the final 48 hour
incubation, all cells (adherent and non-adherent) were harvested and the supernatants
were saved for cytokine ELISA. Adherent cells were removed by gentle scraping and
pooled with the non-adherent cells. In a separate set of experiments, adherent and non-
adherent cells from each well were collected separately. Each population was counted
and then analyzed by flow cytometry. In all cases, cultured cells were washed twice in
PBS- l % FC in the presence of 0. 1 % sodium azide and prepared for flow cytometry.
Genome-wide scan
(NOD x C57BL/6. )Fl C57BL/6. N2 generation mice were generated
by backcrossing female Fls with male C57BL/6. mice. N2 generation mice as well
as (NOD x C57BL/6. )Fl and C57BL/6. control mice, aged 7-8 weeks were
treated with a single DST and four 0.5mg does anti-CD154 mAb as described above
followed by placement of a C3H/eJ skin allografts and monitored for allograft survival.
Upon rejection, liver and tail tissue was collected and frozen immediately on dry ice.
Genomic DNA processed from the frozen tissue was used for 2 cM microsattelite
mapping at the Jackson Laboratory. Results were analyzed using the R/qtl softare
package (htt://ww . biostat.jhsph.edu/ kbroman/ qtl).
Statistics
Average duration of graft survival is presented as the median. Graft survival
among groups was compared using the method of Kaplan and Meier (161). The equality
of allograft survival distributions for animals in different treatment groups was tested
using the log rall statistic (161). P values -:0.05 were considered statistically significant.
Comparisons of two means used unpaired t-tests (162). Comparisons of three or more
means used one-way analysis of variance and the LSD procedure for a posteriori
contrasts (163). To determine the half- life of MRI in sera of treated animals, single-
phase exponential decay curves were fitted by regression analsysis using Prism softare
(Version 3. , Graphpad Softare, Inc. , San Diego , CA).
CHAPTER I
NOD MICE GENETICALLY PROTECTED FROM TYE 1 DIABETES
REMAIN RESISTANT TO TRASPLANTATION TOLERACE INUCTION
Introduction to Chapter I
Our laboratory has demonstrated a generalized resistance to transplantation
tolerance in the NOD mouse. This conclusion was reached because both spontaneously
diabetic and prediabetic NOD mice treated with DST and anti-CD 1 54 mAb rapidly reject
a skin allograft that is not the target of the autoimmune attack (12). This treatment
induces long-term allograft survival in non-autoimmune prone strains (27, 164, 165). It
remains unknown, but generally assumed that the generalized defect to tranpslantation
tolerance induction in the NOD mouse is caused by the ongoing autoimmune process
and/or controlled by the same genetic (Idd) loci that mediate autoimmune diabetes in this
strain (152). To test this hypothesis, we studied various congenic stocks of NOD mice
that bear one or a few resistance alleles at powerful non-H2 Idd loci. These mice were
tested for their response to transplantation tolerance induction with DST and anti-CD 154
mAb. The congenic mice have varying degrees of diabetes expression and some are
almost completeiy protected from disease (Table 3). We reasoned that if NOD-origin
Idd loci are also responsible for the generalized defect to transplantation tolerance
induction, the congenic introgression of one or a few diabetes resistance alleles from a
transplantation tolerance susceptible strain might improve allograft survival. Therefore , if
the ongoing condition of autoimmunity is responsible for the defective response to
qp'
transplantation tolerance induction, the con genic stocks with a genetic attenuation of the
disease may respond better to our transplantation tolerance induction protocol.
In the results presented below, we first eliminated two more trivial explanations
for the NOD defect in transplantation tolerance induction: the NOD' s absence of
hemolytic complement and faster clearance of the anti-CD154 mAb. We showed that
tolerance susceptible C57BL/6 mice harboring NOD derived Idd susceptibility alleles
responded to tolerance induction identical to the wild type C57BL/6 strain. We then
demonstrated that NOD Idd congenic strains that are genetically protected from
autoimmune diabetes stil remained resistant to transplantation tolerance induction.
"",
Chapter I Results
1 a. Costimulation Blockade Prolongs Skin Allograft Survival in Mice
Genetically Deficient in C5a and Hemolytic Complement
The NOD mouse has numerous immune defects that may be involved in their
resistance to the induction of transplantation tolerance. One defect that could impact this
strain s response to in vivo antibody therapy is the absence of hemolytic complement due
to their genetic deficiency in C5a (44). To test this, we attempted to tolerize BlO.
con genic mice that genetically differ in the presence or absence of C5a (166). These
congenic mice were treated with DST, anti-CD154 mAb, and C3H/HeJ skin allografts.
As shown in Figure 4A, the genetic absence ofC5a in BlO.D2- mice did not impair
prolongation of skin allograft survival induced by co stimulation blockade (MST=54
days), and in fact, slightly prolonged skin allograft survival as compared to similarly
treated BlO.D2- mice in which C5a was present (MST=39 days, p.:O.Ol).
1 b. Clearance Kinetics of Anti-CD154 mAb Are Normal in NOD Mice
In a related experiment, we sought to determine if NOD mice are resistant to
tolerance induction because of an accelerated clearance rate of anti-CD 154 mAb from the
circulation. We have previously documented that skin allograft rejection in tolerized mice
is inversely correlated with the level of circulating anti-CD154 mAb (26). Cohorts of
NOD and C57BL/6 mice were administered a single 2.0 mg intraperitoneal injection of
anti-CD154 mAb and circulating antibody concentrations were determined beginning on
day 13 and occiasionally thereafter until 40 days after treatment. The antibody levels
plotted over time and the decay curves are presented in Figure 4B. The half- life of
' -
antibody in circulation as determined by regression analysis for NOD and C57BL/6 is
10.7 days and lOA days, respectively. These data document that neither the absence of
hemolytic complement or an accelerated clearance of anti-CD 154 mAb in NOD mice
accounts for their defect in transplantation tolerance induction.
qp'
Figure 4
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Legend to Figure 4: Skin allograft survival in mice genetically deficient in hemolytic
complement and clearance kinetics of anti-CD 1 54 mAb in NOD and C57BL/6 mice.
Panel A: Skin allograft survival was determined in BlO.D2 mice (H2 treated with DST
and anti-CD154 mAb that have (HC or are genetically deficient (He!) in C5a and
hemolytic complement. Male mice 6- 10 weeks of age were treated with 4 doses of 0.
mg anti-CD 154 mAb , a single DST, and given a C3H/eJ skin graft as described in the
Methods. BlO.D2 He! recipients genetically deficient in C5a had significantly prolonged
skin allograft survival as compared to mice with C5a (p -:0. 01). Panel B: In vivo
clearance of anti-CD154 mAb in NOD and C57BL/6 mice. Cohorts of NOD and
C57BL/6 mice received a single intraperitoneal injection of 2.0 mg of anti-CD 1 54 mAb.
On day +14 and periodically thereafter, mice were bled and serum hamster IgG
concentration was determined by ELISA as described in the methods. Clearance rates
were determined by regression analysis for single phase exponential decay. The half-life
of hamster IgG in NOD mice (10.7 days) was not significantly different than in C57BL/6
mice (10.4 days, p=N.
qp'
2. Costimulation Blockade Prolongs Skin Allograft Survival in C57BL/6
Congenic Mice With NOD SusceptibUity Loci
We next tested the hypothesis that selected NOD derived Idd susceptibility loci
are responsible for their defect in peripheral tolerance induction by co stimulation
blockade. This was first assessed by determining if the ability to prolong skin allograft
survival was abrogated in C57BL/6 mice congenic for various NOD derived Idd loci
(153). None of the C57BL/6 congenic mice develop insulitis or diabetes (Table 3). We
tested four congenic strains. C57BL/6.NODc1c mice carr the NOD derived Idd5.
region which includes genes encoding CD152 (CTLA4) and CD28 , co stimulatory
molecules that are important for tolerance induction and immune activation.
C57BL/6.NODc1 t mice carr the NOD derived Idd5. as well as the Idd5. region that
includes the CXCR2 and IL-8 receptor genes. C57BL/6.NODc3 mice carr the NOD
derived Idd3, Idd17, IddlO and Iddl8 loci, which include genes that control cell
activation. C57BL/6.NODc6 mice carry the NOD Idd6 locus that includes genes
contained within the NK-Pl complex (Table 3).
The median skin allograft survival time of each of these C57BL/6 congenic
strains ranged from 62 to 93 days and were statistically similar to that observed in
C57BL/6 wild-type mice (MST=81 to 94 days Table 4). Skin allograft survival in the
C57BL/6 congenic mice was significantly greater than that observed in similarly treated
NOD mice (MST=20 to 24 days Tables 5 and 6).
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Legend to Table 4: Skin allograft survival on C57BL/6 mice congenic for NOD Idd
intervals. Recipient mice of either sex 6- 10 weeks of age were treated with 4 doses of
anti-CD 1 54 mAb (0.25 or 0.5 mg/dose, as indicated), a single DST, and skin grafted as
described in the Methods. No significant differences in skin allograft survival were
observed between any of the groups (p = N.
3. Diabetes Resistant NOD Congenic Mice Treated with DST and anti-CD154
mAb Rapidly Reject Skin Allograft
We next determined if NOD stocks congemc for selected C57BL/6- or
C57BL/10-derived Idd loci that mediate protection from insulitis and diabetes would also
exhibit prolonged skin allograft survival after treatment with DST and anti-CD 1 54 mAb.
Three groups of NOD congenic mice with intervals that encompass the non-MHC Idd
loci with the greatest effect on diabetes expression were tested (154-157). The first of
these were NOD congenic stocks carring a C57BL/6 derived Idd3 or C57BL/I0 derived
Idd5 locus alone or in combination. These NOD single Idd congenic mice each have a
reduced frequency of diabetes, and when the Idd3 and Idd5 resistance loci are combined
the frequency of diabetes is reduced to 1 % and insulitis is absent in most mice (154) (see
Table 3). The median survival time of C3H/HeJ skin allografts in these NOD congenic
mice treated with DST plus anti-CD 154 mAb (24 to 31 days) was statistically
significantly shorter than that of C57BL/6 mice (::115 days, Table 5). Skin allograft
survival in these NOD congenic mice was similar to that of NOD/Lt (MST=20 days) or
NODlMkTac (MST=23 days Table 5) mice.
We next tested NOD congenic mice that carried various combinations of
C57BL/6 derived Idd3 , IddlO and Idd18 resistance loci. The incidence of diabetes in
these NOD congenic mice varies from 9 to 50% (Table 3). Significant reduction in the
frequency of insulitis is also observed in NOD.B6 Idd3/10/18 triple congenic mice (157
167). Again, all of the NOD congenic strains with various combinations of these genetic
qp'
: I,
\dt
intervals were resistant to tolerance induction, and had median skin allograft survival
times of 17 to 29 days (Table 6).
Finally, we tested a NOD stock congenic for the C57BL/10 derived Idd9 locus.
This locus contains molecular variants of Cd30, Tnfr2 and Cd137 (155) and these mice
have a diabetes incidence of only 3% (Table 3). The median survival time of skin
allografts in NOD.BlO Idd9 mice was 20 days, similar to that observed in NOD/Lt mice
(MST=24 days Table 6).
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Legend to Table 5: skin allograft survival on Idd3/Idd5 congenic NOD mice. Recipient
mice of either sex 6-10 weeks of age were treated with 4 doses of 0.5 mg anti-CD154
mAb , a single DST, and skin grafted as described in the Methods. *Significant from all
other groups (p -:0.001).
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Legend to Table 6: skin allograft survival on Idd3/IddlO/Idd18 and Idd9 congenic NOD
mice. Recipient mice of either sex 6- 10 weeks of age were treated with 4 doses of 0. 5 mg
anti-CD154 mAb , a single DST, and skin grafted as described in the Methods.
*Significant from all other groups (p .cO.OOl).
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Summary of Chapter I
The data presented in Chapter I eliminate a number of candidates that could
control the resistance of NOD mice to transplantation tolerance induction in NOD mice.
We demonstrate that powerful Idd loci that can profoundly reduce the prevalence of
diabetes in NOD mice are unable to restore susceptibility to transplantation tolerance
induction and reciprocally, NOD-derived Idd susceptibility loci are unable to reduce skin
allograft survival on the tolerance-suscpetible C57BL/6 background. We further showed
that resistance is not due to the absence of hemolytic complement, as skin allograft
survival in tolerized B 10.D2 congenic mice that either have or lack hemolytic
complement is similar. Additionally, more rapid clearance of anti-CD154 mAb in NOD
mice is not responsible for their resistance to tolerance induction. NOD and C57BL/6
mice treated with a single 2.0 mg injection of anti-CD 154 mAb cleared the antibody with
the same kinetics. The half-lives observed in this study are similar to a previously
published report from our laboratory (26).
There are at least two possible interpretations of our data. First, the response of
NOD mice to DST plus anti-CD 1 54 mAb is controlled by genetic intervals distinct from
the Idd loci that control their expression of autoimmune. A second interpretation is that
transplantation tolerance induction and autoimmunity are controlled by the same genetic
pathway, but the threshold for restoration of self tolerance and prevention of
autoimmunity is lower than the threshold required for the induction of transplantation
tolerance. This explanation predicts that while the evaluated single Idd loci or small
combinations of Idd loci are able to improve self-tolerance, the establishment of
""'
transplantation tolerance in NOD mice may require complex combinations of Idd
resistance loci. Distinguishing between these two hypotheses is the focus of Chapter II.
qp'
CHAPTER II
A DOMINANT RESISTANCE TO TRASPLANTATION TOLERACE
INUCTION IN (NOD X C57BL/6)Fl MICE
Introduction to Chapter II
The results obtained in Chapter I using Idd congenic stocks that are genetically
protected from autoimmune diabetes furthered our understanding of the defect in
transplantation tolerance induction in NOD mice. However, it remained unknown from
these studies if this defect is genetically uncoupled from the expression of autoimmunity
or controlled by the same pathway but at a higher threshold for tolerance (72). To test the
threshold" hypothesis, we chose to study a more self-tolerant, NOD-related stock of
mice: first fiial generation (Fl) progeny between the NOD and C57BL/6. The C57BL/6
mouse was chosen as a parental strain because it is both susceptible to transplantation
tolerance induction and resistant to autoimmune diabetes. Additionally, it has been used
as the congenic donor in a majority of the Idd congenic stocks, so its diabetes
resistance/susceptibility loci have been well established. We reasoned, based on several
criteria, that these Fl hybrids have achieved a higher level of self-tolerance. First, (NOD
x C57BL/6)Fl mice are fully heterozygous at all Idd loci and the vast majority of
diabetes susceptibilty alleles are recessive (145, 168). Second, these Fl mice are fully
protected from spontaneous diabetes and remain insulitis-free. Third (NOD x
C57BL/6)Fl mice are completely resistant to diabetes induction with cyclophosphamide
an agent that can induce an autoimmune diabetes-like condition on a susceptible
background (169).
qp'
In this chapter, we demonstrate that (NOD x C57BL/6)Fl hybrids are resistant to
tolerance induction, even though they are completely protected from autoimmune
diabetes. This resistance to tolerance induction is not a maternally inherited trait and not
altered by homozygous expression of some of the most protective Idd resistance loci.
Although a vast majority of the NOD cellular immunological defects are restored, we
document that (NOD x C57BL/6)Fl mice inherit the NOD defects in bone marrow
derived DC maturation as well as CD4+ T cell tolerance. Finally, we show that although
these Fl hybrids are resistant to prolonged skin allograft survival , prolonged islet
allograft survival can be established in these mice.
Chapter II Results
1. (NOD x C57BL/6)F1 mice are resistant to co-stimulation blockade-based
transplantation tolerance
Our laboratory has documented that NOD mice have a generalized defect in their
response to peripheral tolerance induction (12), and that NOD congenic mice bearing
strongly protective Idd diabetes-resistance loci which ameliorate autoimmunity also resist
the induction of prolonged skin allograft survival (Chapter 1)(72). To analyze the genetic
basis for these observations, we generated (NOD x C57BL/6)Fl progeny and measured
skin allograft survival after treatment with co-stimulation blockade.
Consistent with previous reports (12), survival of C3H/HeJ skin allografts on
NOD/Lt mice treated with anti-CD154 mAb plus a single C3H/HeJ donor-specific
transfusion (DST) was brief (MST=25 d Figure 5), whereas on age-matched C57BL/6
mice it was , as expected (12, 27), prolonged (MST ;:98d, p.(O.OOl). Unexpectedly,
survival ofC3H/eJ skin grafts on age-matched (NOD x C57BL/6)Fl mice (MST=34 d),
was much shorter than on C57BL/6 mice (p.(O.OOl), and only slightly longer than on
NOD/Lt mice (p.(O.OOl Figure 5).
NOD mice are ancestrally related to Alloxan-resistant (ALR) mice (170), a strain
that expresses a maternally-inherited genetic resistance to beta-cytotoxic cytokines and
alloxan (171). To exclude the possibility that resistance to transplantation tolerance in
(NOD x C57BL/6)Fl mice was dependent on the strain of the maternal parent, we
generated and tested (C57BL/6 x NOD)Fl mice. The median survival time of skin
..,
- .
allografts in (C57BL/6 x NOD)Fl mice (MST=34 d) was not statistically different than
that observed in (NOD x C57BL/6)Fl mice (MST=34 d, p=N. Figure 5).
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Legend to Figure 5: Skin allograft survival in NOD, C57BL/6 and (NOD x C57BL/6)Fl
mice treated with DST plus anti-CD154 mAb. All mice received a single C3H/eJ DST
consisting of 1 x 10 spleen cells intravenously on day- , four injections of 0.5 mg of
anti-CDl54 mAb intraperitoneally on days - 0 and +4 and a C3H/eJ skin graft on
day 0, as described in the methods. Graft survival is significantly longer in C57BL/6 mice
(p':O. OOl) than in any other strain. (NOD x C57BL/6)Fl and (C57BL/6 x NOD)Fl are
statistically indistinguishable (p=N. ). Both (NOD x C57BL/6)Fl and (C57BL/6 x
NOD)Fl have modestly prolonged graft survival ( 10 days) compared to NOD mice
(p.:O.OOl). The experiment was arbitrarily terminated on day 120; a total of7 mice with
intact grafts were removed from the study between days 98 and 112 for use in other
experiments. Vertical bars indicate mice removed from the study with intact grafts or
alive with intact grafts on day 120.
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2. Fixation of strong diabetes resistance Idd loci to homozygosity does not
increase skin allograft survival in (NOD x C57BL/6)F1 mice treated with
costimulation blockade
In Chapter I (72), we demonstrated that NOD congenic mice bearing resistance
alleles at various Idd loci were stil resistant to transplantation tolerance , even though
expression of autoimmunity was reduced. In (NOD x C57BL/6)Fl mice , all Idd loci are
heterozygous. To determine if transplantation tolerance would be restored in the presence
of homozygous Idd diabetes-resistant loci, we generated (NOD.B6 Idd3 BIO Idd5 
C57BL/6. )Fl and (NOD.BlO Idd9 C57BL/6. )Fl mice. Both Fl hybrids are
homozygous for several diabetes-resistance alleles: Idd3 , Idd5. and Idd5. in (NOD.
Idd3 BIO Idd5 C57BL/6. )Fl mice and Idd9. 1, Idd9. and Idd9, in (NOD.BlO
Idd9 C57BL/6. )Fl mice. Both Fl strains, which are completely protected from
autoimmune diabetes, are heterozygous for all other Idd diabetes-resistant loci
distinguishing the two parental strains.
As shown in Table , homozygous expression of Idd9 or Idd3 plus Idd5 variants
in (NOD x C57BL/6. )Fl mice does not lead to improved skin allograft survival
following co-stimulation blockade. Skin allograft survival in (NOD.B6 Idd3 BlO Idd5 
C57BL/6. )Fl (MST=42 d) and (NOD.BI0 Idd9 C57BL/6. )Fl (MST=37 d)
mice are not statistically significantly different from that observed in (NOD x
C57BL/6. )Fl mice (MST=38 d). Skin allograft survival in C57BL/6.H:?7 mice
(MST=77 days) is statistically significantly greater than in any of the Fl groups (p-cO.
Table 7).
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Legend to Table 7: Skin allograft survival on Fl hybrids of Idd congenic NOD mice
mated with C57BL/6. All mice received a single C3H/HeJ DST consisting of 1 x
spleen cells intravenously on day- , four injections of 0.5 mg of anti-CD 1 54 mAb
intraperitoneally on days -
, -
, 0 and +4 and a C3H/HeJ skin graft on day 
Significantly longer than any other group (p":O.Ol) mice. No other paired comparisons
were statistically different.
1i,
:1:
3. (NOD x C57BL/6)F1 mice express abnormalities in dendritic cell
maturation
To begin to understand the cellular basis for the inability of co-stimulation
blockade to prolong skin allograft survival in (NOD x C57BL/6)Fl mice, we investigated
dendritic cell maturation. Dendritic cells are regulators of immunity and self tolerance
(172, 173) and have an important role in transplantation tolerance (143, 174, 175).
Maturation of dendritic cells is dependent on CD40-CD154 interaction (176), and NOD
mice have abnormalities in dendritic cell maturation (129- 133 , 177- 180).
The proportion of total bone marrow-derived anti-CD40 mAb-stimulated and
unstimulated CD86high dendritic cells is low in both (NOD x C57BL/6)FI and NOD/Lt
mice
We cultured bone marrow in the presence of GM-CSF and IL-4 for 6 days , in
some cases adding an agonist anti-CD40 mAb for the last 2 days. The total cell
population (adherent and non-adherent) was recovered on day 6. The proportions of
CD40 mAb stimulated CDllb+CDllc+ dendritic cells expressing high levels of CD86
were high in C57BL/6 mice (36.3 :J 4. , N=4) and significantly lower in both NOD
(16.5:J 8. , p:'O. , N=4) and (NOD x C57BL/6)Fl mice (23.7:J 8.3%, p:'0. , N=3).
Levels in the NOD and (NOD x C57BL/6)Fl mice were similar (p=N. ). Representative
histograms are shown in Figure 6.
These overall results using pools of adherent and non-adherent cells suggest that
both NOD and (NOD x C57BL/6)F 1 dendritic cells fail to mature and are consistent with
several previous analyses of NOD dendritic cells (129, 130, 133 , 177 , 179). However
qp', ' ':',
- =.-'!\-
others have reported that the abnormality of NOD dendritic cells is not immaturity but
rather hyper-activation (131 , 132 , 181). These discrepancies could be related both to the
developing autoimmune state in the NOD mouse and/or to the particular subpopulation of
cultured cells that was analyzed. To confirm that dendritic cells from (NOD x
C57BL/6)Fl mice (which are free of autoimmunity) are truly NOD-like, we proceeded to
evaluate comprehensively the phenotype of adherent (immature) and non-adherent
(mature) dendritic cells generated in the presence and absence of anti-CD40 mAb
stimulation.
The proportion of non-adherent stimulated CD86high dendritc cells in (NOD x
C57BL/6)FI mice is intermediate between that of NOD/Lt mice (low) and C57BL/6 mice
(high)
Following incubation in the presence of an agonist anti-CD40 mAb, the
percentage of non-adherent dendritic cells that expressed CD86 was higher in C57BL/6
(51.7:I 13. , N=3) than in NOD (26.5 :I 1.6%; N=3 , pc(0.005) or (NOD x C57BL/6)Fl
(37. 8:I 4.4%; N=3 , pc(O.Ol) bone marrow cultures. While trending towards higher levels
the proportion of CD86 positive non-adherent dendritic cells generated from (NOD x
C57BL/6)Fl marrow was not significantly different from that of the NOD cultures.
Representative histograms are shown in Figure 7 (right column, solid lines). The level of
CD86 expression on the non-adherent cells was significantly higher in NOD (MFI=1468
:I 174; pc(0.03) and in (NOD x C57BL/6)Fl (MFI=1397 :I 260; pc(0.02) cultures than in
C57BL/6 (MFI=10ll :I 189).
...%: 
i"d
The proportion of non-adherent, unstimulated CD86high dendritc cells in (NOD x
C57BL/6)FI mice is intermediate between that ofNOD/Lt mice (low) and C57BL/6 mice
(high)
Consistent with the data from stimulated cultures, we observed a similar pattern in
unstimulated cultures. The percentage of CD86high non-adherent cells in the C57BL/6
cultures (19.4:: 3.7%) was higher than that in cultures of NOD (7.3 :: 0.4%; p 03) or
(NOD x C57BL/6)Fl bone marrow (11.4 :10.6%; p Figure 7). However, the level
of CD86 expression on non-stimulated, non-adherent dendritic cells was significantly less
in the C57BL/6 (MFI=745 :: 177) than in NOD (MFI=1l58 :: 26; p Ol) or (NOD x
C57BL/6)Fl cultures (MFI=lOl5 :: 152; Ol).
Bone marrow cultures of (NOD x C57BL/6)FI and NOD mice generate larger numbers
of immature adherent dendritic cells than do C57BL/6 mice
We next determined the percentage and number of CD86high adherent dendritic
cells in cultures stimulated with anti-CD40 mAb. The percentage of CD86high adherent
dendritic cells was slightly higher in C57BL/6 (7.6:: 1.0%) than in NOD (3.9:: 1.1%;
Ol) or (NOD x C57BL/6)Fl (3. 8 :: 0.5%; p 004) bone marrow cultures.
Representative histograms are shown in Figure 7 (right column). C57BL/6 bone marrow
(4.3 ::0.7 x 10 cells/well) generated fewer adherent CDllb+CDllc+ cells thim did
cultures of NOD (5.8:: 0.6 x 10 cells/well
, p
05) or (NOD x C57BL/6)Fl (6.6:: 0.8 x
cells/well; p 02) origin (Figure 7). The number of adherent cells generated in
cultures of NOD and (NOD x C57BL/6)F1 bone marrow was similar (p=N.
This data are consistent across CDl1b+CDl1c+ dendritic cell sub populations and
reveals that there is an overall increase in the number of adherent dendritic cells
expressing low levels of CD86 in cultures of NOD and (NOD x C57BL/6)Fl bone
marrow. This leads to a decrease in the percentage of CD86high dendritic cells that
develop in the total culture (Figure 6). Although their percentages are decreased, it is
important to note that the mature non-adherent dendritic cells that do develop from NOD
and (NOD x C57BL/6)Fl bone marrow express higher levels of CD86 than those of
C57BL/6 origin.
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Legend to Figure 6: Maturation of total dendritic cells recovered from bone marrow
cultures of NOD , C57BL/6 and (NOD x C57BL/6)Fl mice. Bone marrow-derived
dendritic cells from NOD (upper panels), C57BL/6 (middle panels), and (NOD x
C57BL/6)Fl (lower panels) mice were incubated in the presence or absence of an agonist
anti-CD40 mAb as described in the Methods. Each culture consisted of a pool of
combined adherent and non-adherent cells from two mice. Cells recovered after culture
were analyzed by flow cytometry. Representative dot plots of CD 11 b + CD 11 c + dendritic
cells obtained from anti-CD40 mAb-stimulated cultures are shown in the left column.
Gating was similar for plots for dendritic cells obtained from unstimulated cultures. The
right column shows the distribution ofCD86 (B7.2) expression on stimulated (solid lines)
and unstimulated (dotted lines) dendritic cells. The horizontal bars in the right column
indicate the gate used for counting CD86high cells. The number above each horizontal bar
indicates the percentage of CD86high dendritic cells in the anti-CD40 mAb-stimulated
cultures. The number below each horizontal bar indicates the percentage of CD86high
dendritic cells in the unstimulated cultures. Isotype controls are shown in the insets;
levels of non-specific CD86 staining were uniformly ..0.3%. Shown are representative
histograms; the experiment was repeated 3 times with similar results. Average
percentages for all three trials are given in the Results.
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Legend to Figure 7: Maturation of adherent and non-adherent dendritic cells recovered
from bone marrow cultures of NOD, C57BL/6 and (NOD x C57BL/6)Fl mice. Bone
marrow-derived dendritic cells from NOD (upper panels), C57BL/6 (middle panels), and
(NOD x C57BL/6)Fl (lower panels) mice were incubated in the presence or absence of
an agonist anti-CD40 mAb as described in the Methods. Each culture consisted of a pool
of cells from two mice. Cells recovered after culture were analyzed by flow cytometry.
Histograms in the left column show the expression of CD86 on adherent CD 11 b + CD 11 c 
cells. Histograms in the right column show the expression of CD86 on non-adherent
CDllb+CDllc+ cells. The horizontal bars in each histogram indicate the gate used for
counting CD86high cells. The number above each horizontal bar indicates the percentage
of CD86high dendritic cells in the anti-CD40 mAb-stimulated cultures. The number below
each horizontal bar indicates the percentage of CD86high dendritic cells in the
unstimulated cultures. Isotype controls are shown in the insets; levels of non-specific
CD86 staining were uniformly ..0.3%. Shown are representative histograms; the
experiment was repeated 3 times with similar results. Average percentages for all three
trials are given in the Results.
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4. (NOD x C57BL/6)F1 mice genetically deficient in CDS+ T cells are
resistant to transplantation tolerance
Allograft survival in recipients treated with DST and anti-CD154 mAb requires
the deletion of alloreactive CD8+ T cells (26, 96). As a part of the analysis of cellular
defects that might be responsible for the resistance of (NOD x C57BL/6)Fl mice to
costimulation blockade, we generated (NOD x C57BL/6)Fl CDSa l- mice. These (NOD x
C57BL/6)Fl CDSa l- mice were used to determine if the failure to delete alloreactive
CDS+ T cells in response to co stimulation blockade was responsible for their resistance to
transplantation tolerance induction.
Three groups of CDSa l- mice (NOD, C57BL/6 and (NOD x C57BL/6)Fl) were
randomized and given DST plus anti-CD154 mAb. Median graft survival in C57BL/6
CDSa l- mice was? 1 0 1 days and 5 of S grafts were intact at the end of the experiment
(Table 8). Duration of skin allograft survival in NOD CDSa l- mice (MST=21 d) was
significantly shorter than C57BL/6 CDSa l- (p=0.005). Graft survival in (NOD x
C57BL/6)Fl CD8a l- mice (MST=35 d) was significantly less than that observed in
C57BL/6 CDSa l- mice (p-(O. Ol) but slightly longer than in NOD CDSa l- mice (p=0.
Table 8). These data document that resistance of alloreactive CD8+ T cells to deletion by
co-stimulation blockade cannot be the sole mechanism ofresistance of NOD and (NOD x
C57BL/6)Fl mice to transplantation tolerance.
We also tested anti-CD 1 54 mAb monotherapy in these animals because we have
previously observed that it somewhat prolongs skin allograft survival in C57BL/6
CDSa l- mice (96). Using anti-CD154 mAb monotherapy, we observed uniformly brief
qp'
skin allograft survival in all three groups: NOD CD8cC
/- 
mice (MST=17 d, N=8),
C57BL/6 CD8a /- mice (MST=23 d, N=12) and (NOD x C57BL/6)Fl CD8a /- mice
(MST=20 d, N=7). None of these MSTs were statistically different.
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Legend to Table 8: Survival of skin allografts on NOD, C57BL/6 and (NOD x
C57BL/6)Fl mice genetically deficient in CD8a. Appropriate mice received a single
C3H/HeJ DST consisting of 1 x 10 spleen cells intravenously on day- , and/or four
injections of 0.5 mg of anti-CD 154 mAb intraperitoneally on days - 0 and +4 and a
C3H/HeJ skin graft on day O. Some mice received a C3H/eJ skin graft only. I
significant difference between groups. 2Significantly different from C57BL/6 mice
(p.:0.003). 3Significantly different from similarly treated NOD (p':O.Ol) and C57BL/6
(p.:0.03).
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5. Natural kiler cell number and cytotoxic activity are similar in (NOD x
C57BL/6)F1 and C57BL/6 mice
NK cells are important in the rejection of allogeneic hematopoietic grafts (113),
and NOD mice have a deficiency in NK cell activity (35 , 107). The role of NK cells in
co-stimulation blockade-induced transplantation tolerance is unknown. We therefore
compared NK cell number and activity in NOD (NOD x C57BL/6)Fl mice to determine
, like the NOD dendritic cell abnormality, it is a genetically dominant trait. Because
NOD/Lt mice are NKl. , we quantified the number of NK cells by dual label analysis
using the DX5 anti-NK cell and anti-ASGM- l antibodies (35). The percentage of
DX5+ ASGM- l + cells in the spleen of C57BL/6 mice (2.18 :: 0.43%, N=6) is greater than
that in NOD/Lt mice (1.68 :: 0.31 %, N=6); this difference was not statistically significant
(p,0. 06), but trended in the same direction as reported by others (35) (Figure 8A). The
percentage of DX5+ ASGM- + cells in the spleen of (NOD x C57BL/6)Fl mice (1.88 ::
28%, N=6) was similar to that detected in C57BL/6 mice (p=N. ) and in NOD/Lt mice
(p=N.
To assess NK kiling activity in these same mice , we measured the cytotoxic
activity of spleen cells against NK-sensitive Y AC- l targets. Interestingly, the NK cell
cytotoxic activity of spleen cells from (NOD x C57BL/6)Fl mice was similar to that of
spleen cells from C57BL/6 mice, both of which were more significantly more potent than
that of spleen cells from NOD mice (Figure 8B).
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Legend to Figure 8: Splenic NK cell percentages and function in NOD, C57BL/6 and
(NOD x C57BL/6)Fl mice. Panel A: Spleen cells were obtained from 6- 12 week old
NOD, C57BL/6, and (NOD x C57BL/6)Fl and stained with DX5 (vertical axis) and anti-
ASGM- l (horizontal axis) antibodies as described in the Methods. The circular gates
indicate the percentage of total splenic lymphocytes that were DX5+ ASGM- l + NK cells.
Shown are representative contour plots. Each analysis was performed 6 times with
similar results. Average percentages for all trials are given in the Results. Shown in the
insets is staining of ASGM- l and the isotype control for the DX-5 mAb. Panel B:
Cytotoxic activity directed against NK -sensitive Y AC- l target cells as determined by
Cr release. Effector cells were spleen cells recovered from 6- 12 week old NOD
C57BL/6 and (NOD x C57BL/6)Fl mice and assayed as described in Methods. Mice
were treated with a single injection of poly I:C 24 hours before spleen cell recovery.
Shown are the results of three independent experiments.
qp'
6. Macrophage maturation in (NOD x C57BU6)F1 mice is normal
NOD mice have defects in macrophage maturation that have been associated with
their resistance to transplantation tolerance (12). Macrophage maturation can be
quantified by measuring the secretion ofIL- lp by bone marrow-derived macrophages
stimulated with LPS (184). Bone marrow from NOD/Lt, C57BL/6 , and (NOD x
C57BL/6)Fl mice was cultured in the presence of CSF- l and IFN-y to generate
macrophages. Cultures were then stimulated with LPS to induce secretion of IL- lp,
which was in turn measured in a thymocyte co-stimulation proliferation assay (184).
As expected, LPS-stimulated macrophages derived from NOD/Lt cultures
produced less IL- lP than did LPS-stimulated macrophages derived from C57BL/6
cultures (Figure 9, p-:O.OOl). Surprisingly, (NOD x C57BL/6)Fl-derived macrophages
responded to LPS by secreting high levels of IL- l p that were comparable to those of
C57BL/6 macrophages (p=N. ). Results of two independent trials were similar. These
results indicate that unlike the genetically dominant dendritic cell defect in the NOD
mouse , the NOD macrophage maturation defect is not expressed in (NOD x C57BL/6)Fl
mIce.
Figure 9
12000
10000
:: 8000
() 6000
34000
2000
C57BL/6 NOD (NOD x C57BL/6)Fl
Legend to Figure 9: Mitogen-stimulated production of IL- by cultures of bone
marrow-derived macrophages from NOD, C57BL/6 and (NOD x C57BL/6)Fl mice.
Pools of bone marrow-derived macrophages were obtained from NOD, (NOD x
C57BL/6)Fl , and C57BL/6 mice, stimulated with LPS , and assayed for production ofIL-
as described in the Methods. Vertical bars indicates incorporation of eH)thymidine by
C3H/HeJ thymocytes in a co-mitogenic assay. Shown is a representative experiment of
supernatants from a bone marrow-derived macrophage culture generated from a pool of
two mice. The data represent the mean :t 1 s.d. of eH)thymidine incorporated in 6
replicate wells for each strain. The experiment was repeated 2 times with similar results.
7. (NOD x CS7BL/6)F1 mice have normal percentages of CD4+CD2S+ T cells
The poor allograft survival in NOD CD8a f- and (NOD x C57BL/6)Fl CD8a
mice suggests that the resistance to transplantation tolerance could in part be due to an
abnormal response of CD4+ T cells, in particular CD4+CD25+ regulatory T cells known
to be important in transplantation tolerance (86, 185- 187). To begin to address this
possibility, we measured the percentage of splenic CD4 CD25+ T cells. We found that
the percentage of CD4+ cells that co-expressed CD25 in C57BL/6 (10.64% :! 1.97%
N=6) was similar to that in both NOD (11.03 :! 1.67%, N=6) and (NOD x C57BL/6)Fl
(11.04:! 3.14%, N=6) mice. Representatitve dot plots are shown in Figure 10.
These results suggest that a deficiency in the percentage of CD4 CD25+ T cells is not
responsible for the abnormal response of (NOD x C57BL/6)Fl mice to co-stimulation
blockade. However, the data do not exclude the possibility of a functional abnormality in
their CD4+CD25+ regulatory T cells.
Figure 
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Legend to Figure 10: Splenic CD4 CD25+ T Cells in NOD, C57BL/6 and (NOD x
C57BL/6)Fl mice. Spleen cells from 6-8 week old NOD (upper panel), C57BL/6 (middle
panel) and (NOD x C57BL/6)Fl (lower panel) mice were stained with anti-CD4
(horizontal axis) and anti-CD25 (vertical axis) mAbs and analyzed by flow cytometr.
The percentage of CD4+ cells that are also CD25+ is indicated in the upper right of each
plot. Shown are representative dot plots; the experiment was repeated 2 times using a
total of 6 individual mice in each group with similar results. Average percentages for all
mice are given in the Results.
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8. Transplantation tolerance to allogeneic islets is normal 
(NODxC57BU6)F1 mice
Finally, we hypothesized that the absence of autoimmunity in (NOD x
C57BL/6)Fl mice may be sufficient for restoration of the induction of transplantation
tolerance to islet allografts in mice, irrespective of their continued resistance to the
induction of tolerance to skin allografts. This hypothesis is based in part on our
observation that transplantation tolerance to islet allografts does not lead to
transplantation tolerance to skin allografts (188). To test this hypothesis , we determined
the ability of co-stimulation blockade to prolong islet allograft survival in chemically
diabetic male NOD mice. We have previously shown that 40% of islet allografts survive
indefinitely in C57BL/6 mice treated with anti-CD 1 54 mAb monotherapy, and essentially
all survive following treatment with DST plus anti-CD 1 54 mAb (189, 190).
Islet allograft survival in chemically diabetic NOD mice treated with anti-CD 154
mAb monotherapy (MST=43 d) or DST plus anti-CD154 mAb (MST=43 d) was
prolonged (Table 9) as compared to that previously observed for islet allograft survival
in spontaneously diabetic NOD mice (12). However, the survival of islet allografts in
chemically diabetic NOD mice remained significantly shorter than in comparably-treated
C57BL/6 mice (MST=::98 d and ::89 d, respectively, Table 9). Histological analysis
revealed complete destruction of the NOD islet grafts instead of selective p cell loss. The
histological data suggest that an alloresponse mediated the rejection of allogeneic islets in
chemically diabetic NOD mice. However, an autoimmune component of islet graft
destruction, can t be ruled out.
J..
101
In sharp contrast to the resistance of (NOD x C57BL/6)Fl mice to skin allograft
tolerance induction, and in contrast to the short survival of islet allografts in chemically
diabetic NOD mice, chemically diabetic (NOD x C57BL/6)F 1 mice treated with anti-
CD154 mAb mQnotherapy (MST=?96 d) or DST plus anti-CD154 mAb (MST=?96 d)
exhibit long term islet graft survival (Table 9). The survival of islets in (NOD x
C57BL/6)F 1 mice is not statistically significantly different from that achieved in
C57BL/6 mice (Table 9).
These data document that the genetically-dominant resistance of (NOD x
C57BL/6)Fl miceto prolonged skin allograft survival by co-stimulation blockade does
extend to resistance to induction of islet allograft tolerance. These data sugguest that
induction of transplantation tolerance to skin allografts requires cellular and genetic
mechanisms that at least partially differ from those required for tolerance induction to
islet allografts, or alternatively, that there is a common genetic basis for islet cell
autoimmunity and resistance to the induction of islet allograft transplantation tolerance in
NOD mice.
T
a
bl
e 
9
St
ra
in
A
nt
i-C
D
15
4
m
A
b
Is
le
t A
llo
gr
af
t S
ur
vi
va
l (
Da
ys
)
M
ed
ia
n 
Su
rv
iv
al
D
ST
Ti
m
e 
(D
ay
s)
N
O
D
 No
 No
 
7
-
-
-
-
-
-
-
_
.
.
_
_
.
_
-
-
-
-
-
_
.
.
-
-
-
-
-
-
_
.
_
-
_
.
_
_
_
h'_
_-
-_
--
'-
"
-
,
-
-
-
-
-
"
-
-
-
'-
,
'
'_
M
,
-
_
_
-
,
-
,
,
-
,
,
-
-
-
-
-
-
,
-
-
,
,
,
_
_
_
_
'_
M
.M
'_
"
_
M
__
M
"_
-_
--
--
--
-'-
--
--
'--
"'-
--
'--
"-
--
-'-
-'-
--
--
.--
.--
.--
--
--
-..
-..
--
-..
-.-
--
..
.
.
-
-
-
-
-
-
-
-
.
-
-
.
-
-
-
-
-
-
-
-
-
-
-
.
-
-
-
N
O
D
 Ye
s N
o
 
12
49
 
N
O
O
---
---
---
'--
---
-'-
---
---
'--
---
---
-'-
--'
-'-
-
'-
-
-
-
-
-
-
-
-
-
Y
es
--
'-"
-"
--
-
-
Y
es
-'-
-
28
:
f(C
64
---
---
---
---
'-'
-
-
-
-
-
-
'-
-
-
-
'-
'-
-
-
-
-
-
'-
-
-
-
'-
-
-
f--
'-
-
-
-
-
-
-
-
-
-
-
-
C5
7B
L/
6 
N
o 
N
o
 
3
,
 
11
 
-
-
-
-
-
-
-
-
-
-
-
-
'-
'-
-
'-
-
-
-
-
-
-
-
-
-
'-
'-
-
-
-
-
-
-
-
-
-
-
-
'.
'-
-
'-
-
-
-
-
.
-
.
.
-
.
-
-
-
.
.
.
-
-
-
-
-
.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
,
.
.
-
-
-
-
.
.
-
-
-
-
-
-
-
.
-
.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
.
,
.
-
,
.
-
-
-
-
-
-
-
-
-
-
.
-
-
-
.
.
.
-
-
-
.
-
-
-
.
-
-
-
-
-
.
.
-
-
.
-
-
.
.
-
-
.
-
-
.
.
.
-
.
-
-
-
-
-
-
-
-
-
-
.
-
-
.
-
-
.
-
-
-
-
-
-
-
-
-
C5
7B
L/
6 
Y
es
 No
 
12
99
 
-
-
-
-
-
-
'-
-
-
-
-
'-
-
-
-
-
-
-
-
"
-
-
"
'-
-
"
-
-
-
-
-
-
-
-
-
-
-
'-
-
-
-
"
-
"
-
-
-
-
-
-
-
-
-
,
-
-
-
-
-
-
-
-
-
"
-
-
-
"
'-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
"
-
-
-
'-
'-
-
-
-
_
.
_
-
-
-
-
-
-
-
-
-
-
_
.
.
_
.
_
-
_
.
_
_
.
_
-
-
_
.
.
_
-
-
-
-
-
-
-
-
-
_
.
_
_
.
_
.
_
-
-
-
-
-
'-
-
-
-
"
.
_
-
'-
-
"
-
-
'-
-
-
-
'
C5
7B
L/
6 
Y
es
 Ye
s
 
78
96
 
(N
OD
 x
 C
57
BL
/6
)F
l 
N
o 
N
o 
N
ID
 
N
ID
-
_
.
.
.
_
_
._
-
-
-
-
-
-
-
-
-
_
.
_
_
.
_
-
_
.
_
.
.
_
-
-
_
.
_
.
_
_
.
_
.
_
-
_
.
.
.
-
-
_
.
_
_
.
.
.
_
_
.
_
.
.
_
-
.
.
.
_
-
_
.
_
-
_
.
.
_
-
_
.
.
_
-
-
-
_
.
_
-
-
-
_
.
.
_
_
.
_
-
-
-
-
-
-
_
.
.
.
_
.
_
-
-
_
.
.
_
-
-
-
-
-
-
_
.
_
.
_
-
-
_
.
-
_
.
.
-
.
_
-
-
-
_
.
_
_
.
.
.
_
-
-
_
.
_
-
_
.
-
_
.
_
.
_
-
-
-
.
_
-
-
-
_
.
_
-
-
_
.
.
_
-
-
-
_
.
_
-
_
.
_
_
.
.
(N
OD
 x
 C
57
BL
/6
)F
l 
Y
es
 No
 
39
98
 
.
.
.
.
-
-
-
-
-
-
-
-
-
-
.
.
-
.
-
.
-
-
.
-
-
.
-
-
-
-
-
.
-
-
-
-
-
.
-
-
.
-
-
-
.
-
-
-
.
-
.
-
-
-
-
.
_
-
-
-
.
_
.
.
.
-
-
_
.
_
.
.
.
_
.
_
-
_
.
_
.
_
-
-
-
_
.
.
.
_
-
-
_
.
_
.
.
-
_
.
-
-
-
-
_
.
.
-
-
-
-
-
-
-
-
-
-
_
.
.
.
_
_
.
_
.
_
-
_
_
.
.
.
-
.
_
.
_
_
.
_
-
_
.
_
.
_
-
-
-
-
-
-
-
.
-
.
-
-
-
-
.
.
.
-
-
.
.
.
-
-
-
.
.
-
-
-
.
-
-
-
-
-
.
.
.
-
-
.
.
-
.
-
-
-
.
-
-
-
-
-
-
.
.
.
-
-
-
-
.
-
-
.
.
.
-
.
.
.
-
-
-
.
-
.
.
.
-
-
-
-
-
(N
OD
 x
 C
57
BL
/6
)F
l 
Y
es
 Yes 
99
 
. ... 
, l 
2Jt 103
Legend to Table 9: Survival of islet allografts in chemically diabetic NOD, C57BL/6
and (NOD x C57BL/6)Fl mice. Recipient mice were rendered chemically diabetic by
intraperitoneal administration of streptozotocin (150 mg/kg body weight) and verified to
be hyperglycemic prior to tolerance induction. Appropriate animals received a single
DST consisting of lxl0 C3H/eJ spleen cells intravenously on day - , four injections of
5 mg anti-CD 1 54 mAb intraperitoneally on days -
, -
, +4 and a C3H/eJ islet graft
consisting of 20 islets/gram body weight placed under the kidney capsule on day O. Graft
survival was monitored by blood glucose levels and rejection was defined as a blood
glucose level :;250 mg/dL. N/D, not done.
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Summary of Chapter II
In this series of experiments, we sought to test the hypothesis that resistance to
transplantation tolerance in NOD mice is controlled by the same genetic pathways that
control the breakdown of self tolerance leading to autoimmune diabetes. The hypothesis
posited that a lower threshold is required to establish self tolerance compared to the
ability to induce tolerance to a foreign tissue with co stimulatory blockade. To test this
hypothesis, Fl progeny between various NOD and C57BL/6 stocks were generated, and
they all proved to be resistant to transplantaton tolerance induction even though they are
completely diabetes resistant. The resistance to skin allograft tolerance induction in Fl
mice correlates with dominant NOD defects in dendritic cells and CD4+ T cells.
Surprisingly, (NOD x C57BL/6)Fl mice are readily tolerized to islet allografts with DST
and anti-CD 1 54 mAb, highlighting the tissue specific differences in the genetic control of
transplantation tolerance induction.
While the data presented in this chapter argue against the higher "threshold"
model for transplantation tolerance in NOD mice, the genetic separation of these two
phenotypes cannot be proven by this series of experiments. The true test of the
hypothesis that partially, but not completely overlapping genetic mechanisms control
transplantation tolerance and autoimmunity requires the identification of the loci that
mediate induction of transplantation tolerance induction, which is the fQcuS of Chapter
II.
qp'
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CHAPTER II
IDENTIFICATION OF THE GENETIC iNTERVALS THAT CONTROL
PROLONGED SKI ALLOGRAFT SURVIVAL IN NOD MICE TREATED
WITH DONOR SPECIFIC TRASFUSION AN ANTI-CDI54 mAb
Introduction to Chapter II
To assess whether the genes that determine autoimmunity and resistance to
transplantation tolerance are distinct or overlapping, we chose a genome wide scan
approach. N2 generation mice, generated by backcrossing (NOD x C57BL/6. )Fl
mice to the tolerance-susceptible C57BL/6. strain were treated with DST and anti-
CD 154 mAb and the duration of skin allograft survival measured.
We chose to perform a backcross mating scheme for a few reasons. First, we
were primarily interested in determining the genetic basis for the dominant NOD
resistance to skin transplantation tolerance induction. Secondly, this approach is feasible
because the diabetes-resistant C57BL/6. strain can be used as the backcross parent
thus avoiding the confounding effects of autoimmunity in the N2 generation. Finally, an
Fl intercross strategy, while informative, is more difficult to analyze because
recombination events can occur in both parents and is most useful for mapping recessive
phenotypes; backcross mating strategies are amenable to QTL analysis (191).
Identification of the quantitative trait loci (QTLs) that control the duration of graft
survival wil allow us to localize dominant NOD-derived loci and to determine if these
coincide with the location of previously-defined Idd loci or if new loci are identified.
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QTL analysis has also been used to map a number of other genes in many polygenic
diseases (192). Indeed, this strategy has identified Idd loci in mice, but in contrast to the
experimental design for the experiments described in this chapter, the NOD strain was
used as the backcross parent for the identification of Idd loci since diabetes is a recessive
trait (145). This approach may discover new chromosomal regions that contain genes that
control only the transplantation tolerance defect of NOD mice, but it is equally likely that
these new regions may contain previously unknown dominant NOD-derived genes that
may have overlapping function in autoimmune diabetes. The genome wide scan strategy
is particularly advantageous in comparison with testing existing Idd congenic strains for
tolerance induction (Chapter I) because it is unbiased.
In this chapter, the preliminary results of the genome wide scan on (NOD x
C57BL/6. C57BL/6. backcross progeny are reported. As expected, the skin
allograft survival in response to DST and anti-CD154 mAb is a variable quantitative trait
and four suggestive loci have been identified that control this phenotype: two near
reported Idd loci, and two novel loci. Continuation of this study wil allow for better
resolution of these putatitve transplantation tolerance loci.
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Chapter II Results
1. Skin allograft survival in (NOD x C57BL/6. )F1 x C57BL/6.
generation animals is a polygenic trait.
In Chapter II , we documented a dominant resistance to transplantation tolerance
in NOD mice that is inherited in Fl progeny. To map the genes independent of the MHC
that control this phenotype, we generated N2 mice, treated them with DST and anti-
CD154 mAb , and monitored skin allograft survival. In this initial study, we measured
skin allograft survival on 64 (NOD x C57BL/6. )Fl C57BL/6. backcross mice
along with 16 C57BL/6. and 8 (NOD x C57BL/6. )Fl mice. The median
duration of allograft survival on C57BL/6. and (NOD x C57BL/6. )Fl was 55
days and 35 days (p":O.OOI), respectively (Figure llA). When the frequency distribution
of allograft survival in the N2 generation mice is plotted, we observe that the data is
widely distributed, with a high proportion of the data centered around the median
indicating that duration of skin allograft survival is a polygenic trait (Figure llB).
Figure 11
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Legend to Figure 11: Skin allograft survival on (NOD x C57BL/6. )Fl 
C57BL/6. backcross mice treated with DST and anti-CD154 mAb. Panel A:
Comparison of the distribution of skin allograft survival in NOD C57BL/6. (NOD x
C57BL/6. and backcross mice. Horizontal bars in each scatter plot indicate the
median value for that group. Panel B: Frequency distribution of skin allograft survival in
backcross mice with the best-fit normal distribution curve for the data.
qp':,,:" " ;;:
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2. QTL analysis reveals four suggestive loci mediating the response to
costimulation blockade.
Because polygenic traits are amenable to QTL analysis , we carried out a genome
wide QTL analysis USIng the R/qtl software package
(http://ww . biostat.jhsph.edul kbromanl qtl). Days to rejection was used as the
quantitative trait and, because N2 generation males and females showed a difference in
the median time to rejection (MST = 48 days for males , 30 days for females , p.cO.0001),
sex was included as an additive covariate in the analysis, meaning that we are examining
genetic effects after taking into account the differences between the two sexes.
After analyzing the data, four loci reach a suggestive, but not significant log of
odds (LOD) score, Suggestive thresholds for the single sex genome scan and the
combined scan with sexas a covariate are 1.4 and 2. 8 LOD, respectively. Significant
thresholds for the single sex genome scan and the combined scan with sex as a covariate
are 2. 8 and 4.9 LOD , respectively. The significance thresholds were computed using
permutation analysis (193). A profie of LOD scores across the genome is shown in
Figure 12A. Markers on chromosomes 2, 5 and X are suggestive regardless of sex and a
marker on chromosome 4 is suggestive in males only. Also , the marker on the X
chromosome is more suggestive when males are analyzed separately. The direction and
magnitude of the effect for the four markers: D2Mit190 , D4Mit26 , D5Mit348 and
DXMit64 are shown in Figure 12B. Two markers, D4Mit26 and DXMit64 have effects
in the opposite direction expected, i.e. better allograft survival in heterozygous animals
where a NOD-derived allele is present compared to homozygous expression of the
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C57BL/6-derived allele. The other two markers, D2Mit190 and D5Mit348 have their
effects in the expected direction, i.e. better allograft survival in the mice homozygous for
C57BL/6-derived alleles at the marker.
Figure 12
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Legend to Figure 12: Results of the genome wide scan for QTL controlling
transplantation tolerance induction in NOD mice. Panel A: Profie of LOD scores across
all the chromosomes of the mouse genome from the cohort of mice in Figure 11.
Suggestive and significant LOD scores in the single sex scans are 1.4 and 2.
respectively. For the scan with sex as an added covariate , suggestive and significant
LOD scores are 2. 8 and 4. , respectively. Panel B: Direction and magnitude of the QTL
effects at each of the suggestive loci (bb = homozygous C57BL/6-derived; nb =
heterozygous). Males, closed circles; females, open circles.
1::;:
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Summary of Chapter II
The genome wide scan analysis of (NOD x C57BL/6. )Fl C57BL/6.
backcross progeny treated with DST and anti-CD154 mAb and a skin allograft is a
polygenic trait, as demonstrated by the bell shaped curve of duration of survival in this
preliminary cohort. Since this phenotype is polygenic, it is amenable to QTL analysis.
Indeed , genome wide QTL analysis reveals four suggestive loci and while they don t yet
reach statistical significance, increasing the number of mice in the study wil hopefully
achieve significant thresholds. It is important to note that this study has been designed to
include approximately 300 N2 generation animals and only 64 were included in this
preliminary analysis.
Interestingly, two previously described Idd loci are located very near two of the
suggestive QTL. The two other QTL are not near known Idd loci. The data provide
unbiased support to the hypothesis of "distinct but partially overlapping" genetic control
hypothesis. However, it remains to be determined if the QTL identified on chromosomes
X and 4 also alter the expression of autoimmunity in NOD mice, even though previous
screening by others failed to identify them as Idd loci. It is apparent from these
preliminary studies that the control of transplantation tolerance in NOD mice is
controlled by a complex genetic program.
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DISCUSSION
The goal of this thesis project was to investigate the relationship between genes
that control autoimmune diabetes expression in NOD mice with those controlling their
resistance to transplantation tolerance induced by costimulation blockade. The results in
Chapter I document that single or small combinations of the evaluated C57BL/6-derived
Idd loci that dramatically alter diabetes expression are not able to correct the response of
NOD mice to costimulation blockade and, conversely, that the evaluated NOD-derived
Idd loci do not shorten skin allograft survival in C57BL/6 mice. Chapter II demonstrates
that resistance to skin transplantation tolerance in NOD mice is a dominant trait.
Resistance to skin transplantation tolerance in Fl hybrids correlates with inherited NOD-
like defects in dendritic cells and CD4+ T cells. Finally, the exciting preliminary data in
Chapter II implicates four loci that control resistance to skin allograft transplantation
tolerance: two near known Idd loci and two intervals outside of currently known Idd loci.
The genetic basis of transplantation tolerance induction in NOD mice
Our first genetic approach tested the hypothesis that some of the loci associated
with development of autoimmune diabetes in NOD mice would also be important in their
resistance to induction of peripheral transplantation tolerance. This hypothesis predicts
that in NOD congenic mice harboring C57BL/6 or C57BL/10-derived diabetes resistance
alleles skin allograft survival wil be prolonged and conversely, C57BL/6 congenic mice
harboring NOD-derived diabetes susceptibility alleles wil have abbreviated skin allograft
survival after tolerance induction. Prolonged allograft survival was not abrogated in
C57BL/6 stocks congenic for any of the analyzed NOD-derived Idd susceptibility loci.
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We note, however, that no combination of Idd susceptibility loci introgressed into
C57BL/6 mice to date has rendered them susceptible to the spontaneous development of
insulitis or autoimmune diabetes (153).
Similarly, none of the analyzed C57BL/6- or C57BL/10-derived Idd congenic
intervals that confer various degrees of diabetes resistance to NOD mice restored their
ability to be tolerized to skin allografts by DST and anti-CD 154 mAb treatment. This
observation was surprising because congenic introgression of even a few of the Idd
resistance loci into NOD mice profoundly reduces the incidence of insulitis and diabetes
(154, 155, 194, 195) (see Table 3). Furthermore , many of the tested Idd congenic
intervals are characterized by polymorphisms in genes important for costimulation and
immune activation, giving a plausible explanation why Idd loci could control the
response to transplantation tolerance induction.
It is possible that the results from Chapter I reflect the fact that more Idd
resistance loci are required to genetically alter the phenotype of abnormal transplantation
tolerance induction in NOD mice than are required to decrease the incidence of
spontaneous autoimmune diabetes (i.e. a higher "threshold" must be achieved).
Specifically, peripheral transplantation tolerance induction by co stimulation blockade
may be under the control of a complex combination of Idd loci not yet tested.
Additionally, there could be potential interactions of the unique NOD MHC with
these genetic loci that have an effect on tolerance induction. However, these data raise the
possibility that the loss of self-tolerance leading to autoimmunity in NOD mice may be
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mediated by mechanisms that differ
, in part, from their resistance to peripheral
transplantation tolerance.
The focus of Chapter II was to distinguish between the "genetic threshold" and
the "genetic separation" hypotheses that arose out of the analysis of transplantation
tolerance induction in Idd congenic mice (Chapter I). Previous studies have lent support
to the genetic threshold hypothesis for autoimmunity in NOD mice. These studies used
NOD mice mated with various non-autoimmune strains and treated the Fl mice with
cyclophosphamide to induce diabetes (196, 197). Approximately 30% of NOD female
mice crossed with the closely related but diabetes-resistant MHC-compatible NOR/t
strain developed diabetes using this treatment protocol (198). In another study, NOD
mice were crossed with diabetes- and insulitis-free NOD. mice. Approximately 50%
of (NOD x NOD. )Fl mice developed insulitis , a low percentage (3%) of female Fl
mice spontaneously developed diabetes, and 20% become diabetic after treatment with
cyclophosphamide (199). These data argue for a genetic "threshold" model for expression
of autoimmunity.
In Chapter II, we generated (NOD x C57BL/6)Fl mice to begin to test the
genetic threshold" hypothesis and the possible role of Idd loci in transplantation
tolerance. (NOD x C57BL/6)Fl mice are heterozygous at all Idd loci distinguishing the
two parental strains (168). Only three NOD Idd diabetes-susceptibility loci Idd13, Idd14
and Idd15 (145, 149 , 200-202) are dominant, the remainder are recessive. (NOD x
C57BIJ6)Fl mice treated with cyclophosphamide remain free of diabetes (169),
suggesting that they have a high genetic threshold of resistance to autoimmunity.
ff.
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Therefore, if similar genes control autoimmunity and transplantation tolerance, (NOD x
C57BL/6)F 1 mice should have a higher "threshold" facilitating the induction of
transplantation tolerance. Unexpectedly, (NOD x C57BL/6)Fl mice clearly remain
resistant to the induction of prolonged skin allograft survival by co stimulation blockade.
We further tested the genetic threshold model and a role for Idd loci by generating
(NOD.B6Idd3 BlO Idd5 C57BL/6. )Fl and (NOD.BlO Idd9 C57BL/6. )Fl
mice, which are homozygous for strongly protective diabetes-resistance Idd loci, We
nonetheless observed skin allograft survival in response to costimulation blockade was no
better in these congenic Fl progeny than that in (NOD x C57BL/6)Fl mice.
Finally, we observed that the resistance of skin allograft survival is genetically
uncoupled from islet allograft survival, as (NOD x C57BL/6)Fl mice treated with DST
and anti-CD154 mAb have,prolonged islet allograft survival. This phenotype resembles
the C57BL/6 phenotype and is in contrast to brief islet allograft survival in similarly
treated NOD mice. This phenotype could reflect that the "threshold" to achieve tolerance
to islet allografts is intermediate between self-tolerance and skin allograft tolerance in
(NOD x C57BL/6)Fl mice. Another possibility is that the genetic control of islet, as
opposed to skin allograft survival is mediated by recessive Idd loci that are corrected in
the (NOD x C57BL/6)Fl mice. Ongoing studies with the congenic mice described in
Chapter I wil help to test this possibility.
We conclude from this data that skin transplantation tolerance induction and
susceptibilty to autoimmune diabetes are not likely to be controlled by identical genetic
pathways , since (NOD x C57BL/6)Fl mice have achieved a higher threshold of self-
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tolerance, yet remain resistant to transplantation tolerance induction. Perhaps the
s!rongest piece of data arguing for distinct genetic control is the fact that susceptibility to
diabetes and response to transplantation tolerance induction are differentially inherited in
these Fl hybrids. However, we cannot rule out the possibility that there is partial overlap
between these phenotypes. Indeed, some of the Idd congenic stocks examined in Chapter
I have modestly prolonged skin allograft survival compared to wild type NOD mice
suggesting that diabetes resistance alleles may have a small but detectable influence on
transplantion tolerance induction. Interestingly, skin allograft survival in (NOD x
C57BL/6)Fl mice was also slightly but reproducibly longer than that observed in NOD
mice. Speculatively, this difference could be controlled by a dominant C57BL/6-origin
Idd locus/loci with an unkown phenotype. The modest prolongation of skin allograft
survival in (NOD x C57BL/6)Fl mice compared to NOD mice is not what would be
expected of a dominant or co-dominant phenotype. Rather it suggests that a complex set
of genetic interactions involving several loci is needed for prolongation of allograft
survival in response to co stimulation blockade (203).
The data in Chapter II begin to confirm that the genetic control of prolonged skin
allograft survival in response to costimulation blockade is indeed complex. QTL analysis
on the N2 generation highlights four suggestive markers, two that are near the known
diabetes loci Idd13 on chromosome 2 and Idd15 on chromosome 5. The other two
markers DXMit64 and D4Mit26 , on the X chromosome and chromosome 4
respectively, are not near any known Idd loci. Interestingly, loci on chromosomes 4 and
X are restricted to male mice and opposite of the direction expected. A QTL in the
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opposite direction is not uncommon and can lead to transgressive segregation, where the
progeny have phenotypes that are more extreme than either of the parental lines. Indeed
Idd diabetes susceptibility alleles have been found to be harbored in the genome of
otherwise diabetes resistant strains; introducing a tightly linked Idd locus is one of the
complications of congenic transfer of a gene "knockout" generated on the 129
background to the NOD background (204).
The locus centered around D5Mit348 maps near Idd15 a poorly defined
dominant diabetes susceptibility locus (200). D2Mit190 is near Idd13 a recessive
diabetes susceptibility locus. However, this interval is better defined, containing the both
132M 2 cM from D2Mit190) and the III gene encoding IL- l. The NOD f321v allele is
the only non-MHC gene to date that has been definitively shown to be a diabetes
susceptibility gene (149). nterestingly, the NOD alleles of these transplantation loci on
chromosomes 2 and 5 exert their effects in a dominant manner, meaning that genes in
these regions could be exerting their effects on diabetes pathogenesis and response to
costimulation blockade in a similar fashion.
The preliminary data from the genome-wide scan also suggests that there is some
degree of overlap in the genetic control of skin transplantation tolerance and
autoimmunity, as markers both near Idd loci and markers distinct from known Idd loci
suggestively control the transplantation tolerance phenotype in this study. These data
could reflect that the two phenotypes are controlled at different set points along the same
genetic pathway. However, as this analysis continues, the exact nature of the genetic
control of the transplantation tolerance phenotype wil be elucidated.
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While the genome-wide scan described in this dissertation wil eventually allow
high-resolution genetic analysis, there are genetic interactions and variables not
accounted for by this strategy. A genetic variable that was intentionally fixed in this
backcross experiment is the MHC haplotype. We were specifically looking for loci that
were independent of the MHC , but acknowledge that there probably are interactions
between MHC and non-MHC genes that alter the response to transplantation tolerance
induction. Indeed, the fact that the suggestive marker D2Mit190 is approximately 2 cM
from a known diabetes susceptibility gene that most definitely interacts with genes within
the MHC, i. e. the 132M gene (149), indicates that transplantation tolerance induction is
likely controlled by genetic interactions between MHC and non-MHC genes. To
determine the interactions between MHC and non-MHC genes, the role of the vs.
haplotypes, and other recessive phenotypes involved in transplantation tolerance
induction, a second mapping experiment will need to be undertaken by our laboratory.
This strategy involves intercrossing (NOD x C57BL/6)Fl (not fixed at the MHC) to
generate F2 progeny that wil have the MHC segregating as an additional variable. An
F2 intercross mating strategy has the advantage over a backcross breeding strategy by
picking up recessive phenotypes and epistatic interactions (191). Additionally, future
experiments that mate C57BL/6. mice with C57BL/6.NODc2 (D2Mit274-
D2Mit343) that harbor the NOD Idd13 allele so that both the NOD MHC and p2M are on
the C57BL/6 background wil also aid in determining a role for the interaction of genes in
the MHC and Idd13 (perhaps p2M) in the response to costimulation blockade.
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The cellular basis of transplantation tolerance induction in NOD mice
What is the cellular basis for autoimmune diabetes and transplantation tolerance
induction in NOD mice? The data presented suggest a number of cellular abnormalities
in the immune system of NOD mice that may be important. There is evidence that
autoimmune diabetes in NOD mice is due primarily to defects in central tolerance (34).
Bone marrow chimerism is known to prevent autoimmunity in NOD mice by this
mechanism (205). In humans, bone marrow cells from diabetic donors have been
documented to adoptively transfer disease to non-diabetic recipients , suggesting that
central tolerance defects are also important in type 1 diabetes in humans (64).
Additionally, there are data to suggest that manipulation of the peripheral immune system
can affect self-tolerance and the expression of autoimmune diabetes in NOD mice (23
206, 207). Mechanisms that control central and peripheral tolerance are different. Central
tolerance is primarily mediated by intrathymicdeletion of autoreactive T-cells during
thymic development, whereas peripheral tolerance is mediated by multiple mechanisms
including deletion, anergy, and regulatory processes (9).
It is currently unknown whether improved central or peripheral tolerance is the
mechanism by which the NOD congenic mice we studied in Chapter I were rendered
resistant to autoimmune diabetes. Our data suggest, however, that if the mechanism of
protection from diabetes is due to restoration of the factors that permit peripheral
regulation of autoimmunity, these mechanisms are not sufficient for the induction of
peripheral transplantation tolerance to skin allografts by costimulation blockade.
qp'
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In Chapter I , we eliminated two additional possibilities for resistance to
transplantation tolerance in NOD mice: absence of hemolytic complement and more
rapid clearance of anti-CD 1 54 mAb. Peripheral transplantation tolerance induction by
DST and anti-CD 1 54 mAb involves the deletion of alloreactive CD8 T-cells (26 , 96).
Because CD8+ T -cells in NOD mice appear to be resistant to tolerance induction (54), this
may be one mechanism by which NOD mice are resistant to costimulation
blockade-induced tolerance. However, we have recently determined that the majority of
high-affinity alloreactive CD4+ T -cells are also deleted by treatment with DST and anti-
CD154 mAb (unpublished observations from our laboratory). CD4+ T-cells express
CD154 when activated (158). This suggests that one possible mechanism by which DST
and anti-CD 154 mAb induces tolerance could involve deletion of alloreactive CD4+ T-
cells by antibody-mediated , complement-dependent lysis. However, the ability to prolong
skin allograft survival in con genic B 10.D2 mice that lacked C5a and hemolytic
complement argues that this defect does not prevent tolerance induction in NOD mice.
We have also documented that the circulating level of anti-CD154 mAb is
inversely correlated with skin allograft survival in recipients treated with DST and anti-
CD154 mAb (26). However, the clearance rate of anti-CD 1 54 mAb from the circulation
of NOD mice was similar to that of C57BL/6 mice. These data suggest that rapid
clearance of anti-CD 154 mAb, hence potentially lowering anti-CD 154 mAb
concentrations below effective tolerizing levels (-100 !-g/ml) (26), was not the basis for
the resistance of NOD mice to tolerance induction.
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Examination of various cellular compartents in (NOD x C57BL/6)Fl mice for
dominant NOD-like cellular abnormalities could explain our genetic observations. First
we found that (NOD x C57BL/6)Fl mice exhibit abnormal dendritic cell maturation.
Second, we observed an abnormal response of (NOD x C57BL/6)Fl CD8a f- mice to
costimulation blockade, suggesting a defect in the response of CD4+ T cells in these
animals.
An attractive candidate cell population to explain the resistance to transplantation
tolerance is dendritic cells. Maturation of dendritic cells is abnormal in NOD mice (129-
133 , 177- 179), and dendritic cells are the primary target of CD 154 expressed by activated
CD4+ T cells (176 , 208 , 209). We found that dendritic cells derived from NOD and
(NOD x C57BL/6)Fl mouse bone marrow cultures mature abnormally, even when
stimulated with an agonist anti-CD40 mAb. With respect to NOD dendritic cells, it is also
interesting to note that, although reduced in number, the mature non-adherent dendritic
cells generated by NOD bone marrow expressed higher levels of CD86 than did those
from C57BL/6 controls. These apparently conflcting data on the maturation of NOD
dendritic cells depending on the cell population analyzed may in part explain the
differing reports in the literature that dendritic cells derived from NOD bone marrow
cultures fail to mature normally (129, 130, 133 , 177, 179) or are hyper-activated (131
132).
We also observed that (NOD x C57BL/6)Fl CD8a f- mice remain resistant to
tolerance induction. A requirement for prolongation of skin allograft survival in mice
treated with costimulation blockade is the deletion of host alloreactive CD8+ T cells (26
J...
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, 101 , 102, 210). The resistance of (NOD x C57BL/6)Fl CD8a /- mice to
transplantation tolerance suggests that their CD4+ T cells respond abnormally to
costimulation blockade.
At least three explanations for the brief skin allograft survival in tolerized (NOD x
C57BL/6)Fl CD8a /- mice are possible. First, anti-CD154 mAb may fail to block
alloreactive CD4+ T cell activity. Second, the absence of the CD8a+ dendritic cell subset
in (NOD x C57BL/6)Fl CD8a /- mice may be important (124). This possibility seems
unlikely, however, because we have shown that C57BL/6 CD8a /- knockout mice are
susceptible to transplantation tolerance. Third, there may be defects in the function of
regulatory CD4 CD25+ T cells; these cells are important both for the induction of
transplantation tolerance (86 , 87, 185-187) and for the expression of autoimmunity in
NOD mice (45). We found that NOD/Lt, C57BL/6, and (NOD x C57BL/6)Fl mice have
comparable percentages of small resting CD4 CD25+ spleen cells, but we recognize that
functional defects in CD4 CD25+ T cells could nonetheless be present in (NOD x
C57BL/6)Fl mice.
We speculate that dendritic cell maturation abnormalities and abnormal response
of CD4+ T cells to co stimulation blockade may be causally related in (NOD x
C57BL/6)Fl mice. Costimulatory molecule expression by dendritic cells is important for
modulating CD4+ T cell responses in both autoimmunity (139) and transplantation (141
143, 175), and dendritic cells are thought to control the generation of regulatory
CD4 CD25+ T cells (211-215). It has also been suggested that low expression of CD86
on NOD dendritic cells leads to the failure of CD4+ T cells to up-regulate CTLA-
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contributing to impaired self-tolerance (133). CTLA-4 expression is also critical for the
induction of peripheral transplantation tolerance and regulatory CD4 CD25+ T cells (27
, 216). Finally, NOD mice deficient in CD80 and CD86, the ligands for CTLA-
rapidly develop diabetes, presumably due to deficiencies in regulatory CD4+CD25+ cells
(45).
Additional cell populations defective in NOD mice are NK and NKT cells. Our
observation that NK cell number and cytotoxic activity is normal in (NOD x C57BL/6)Fl
mice suggests that NK cell defects are unlikely to be responsible for the resistance of
(NOD x C57BL/6)Fl mice to tolerance induction. NKT cells appear to playa minor role
in tolerance induced via DST and anti-CD154 mAb (unpublished observations) and
cannot rule out a possible role for NKT cells in skin transplantation tolerance in (NOD x
C57BL/6)Fl mice. Recently, work by our collaborators indicates that NKT cell function
as assessed by in vivo activation with suboptimal doses of anti-CD3 mAb results in an
improved IL-4 response , determined by quantitative R T - PCR (Laurence Peterson
personal communication). We recognize, however, that functions of both NK and NKT
cells not measured in these studies (e.
g. 
cytokine production) could be defective.
Defective macrophage function has previously been associated with impaired self
tolerance and resistance of NOD mice to transplantation tolerance (12 , 126 , 184). Our
analyses of macrophages derived from bone marrow cultures of (NOD x C57BL/6)Fl
mice showed that their macrophage maturation appears to be normal. These data permit
us to separate defects in macrophage maturation from defects in dendritic cell maturation
and resistance to skin transplantation tolerance.
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Finally, it remains to be determined if alloreactive CD8+ T cells in NOD and
r-- (NOD x C57BL/6)Fl mice resist deletion in response to costimulation blockade. Recent
evidence suggests that NOD CD8+ T cells are resistant to deletion in response to
peripheral tolerance induction to soluble antigens (54). In preliminary studies, we have
obtained evidence that all ore active TCR transgenic CD8+ T cells in (NOD x CBA)Fl
mice are also relatively resistant to deletion following treatment with DST plus anti-
CD154 mAb (unpublished observations).
It was surprising that transplantation tolerance to islet allografts is restored in
(NOD x C57BL/6)Fl mice. This might reflect a difference in the requirement for a
regulatory T cell population, as it has been suggested that this cell type is required for
skin but not islet allograft tolerance (188). However, as noted above, the basal numbers
ofCD25+CD4+ T cells appear to be normal in both NOD and (NOD x C57BL/6)Fl mice.
Recently, others have also reported that basal numbers of CD4 CD25+ T cells in
prediabetic NOD mice are similar to other non-autoimmune strains (217). The exact
cellular basis for the difference in skin versus islet allograft survival in (NOD x
C57BL/6)Fl mice remains undetermined.
Summary
Our data documenting resistance to transplantation tolerance in (NOD x
C57BL/6)Fl mice and in congenic NOD mice bearing strongly protective Idd diabetes-
resistant loci (72) (Chapter I) could be due to two different but not mutually exclusive
genetic mechanisms. First, the transplantation tolerance defect could be controlled by the
same genetic loci that control autoimmune diabetes, but the "genetic threshold" for
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restoring susceptibility to transplantation tolerance could be higher than that required to
prevent autoimmunity. Alternatively, the genes that control transplantation tolerance to
skin allografts may be partially or even completely distinct from those that control
autoimmunity .
The data in Chapter II unexpectedly reveal that poor skin allograft survival in
response to co stimulation blockade is a characteristic not only of autoimmune NOD mice
(12 218 219) and NOD congenic mice that bear strongly protective Idd resistance loci
(72) (Chapter I), but also of diabetes-free (NOD x C57BL/6)Fl mice (Chapter II). This
dominant genetic resistance is not a maternally inherited trait and is not corrected by
fixing to homozygosity strongly protective non-H2 Idd diabetes-resistant loci in the Fl
NOD.Idd x C57BL/6 intercross mice. What is most interesting is that transplantation
tolerance to allogeneic islets appears to be normal in (NOD x C57BL/6)Fl mice, meaning
that the genetic control of tolerance to skin versus islet allografts in these mice are
different.
Finally, the preliminary results of Chapter II begin to shed light on the exact
genetic basis of resistance to transplantation tolerance induction. The identification of
two new loci unique from all currently described Idd loci as well as the implication of
two suggestive markers near Idd13 and Idd15 wil need to be verified and the intervals
narrowed. However, this exciting preliminary data wil hopefully lead to important
contributions in the understanding of this confounding phenotype in NOD mice.
The exact genetic basis for resistance to skin allograft transplantation tolerance in
NOD mice remains elusive, as does the exact genetic basis for their susceptibility to
ffi'
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autoimmunity. Our observations suggest that an ongoing autoimmune process, even one
with low penetrance as measured by diabetes, is not responsible for the failure of
tolerance induction in NOD mice. Although we have separated the skin transplantation
tolerance resistance phenotype from the autoimmunity phenotype, we recognize that our
data have not definitively falsified either the higher "threshold" hypothesis or the
distinct or overlapping genes" hypothesis.
Understanding the relationship between transplantation tolerance and
autoimmunity represents an important area of research with implications for curing type 
diabetes by islet transplantation. The assumption that autoimmunity and transplantation
tolerance in NOD mice are controlled by exactly the same genes may be incorrect, and
the data presented herein support this conclusion (Figure 13).
An immediate implication of the current findings concerns the way in which
investigators evaluate tolerance induction protocols eventually intended for the clinic. If
those protocols are evaluated in the NOD mouse, it must be asked if the defect in
transplantation tolerance seen in these animals represents a defect that is likely to be
encountered in people with type 1 diabetes or if it is a unique abnormality restricted to
this mouse model. If the latter should prove true, this raises questions about the utility of
the NOD mouse for modeling costimulation blockade-based transplantation tolerance
induction in type 1 diabetes. Alternatively, the genome-wide scan for loci important in
regulating transplantation tolerance induction may lead to the identification of human
orthologues , much like the Idd- IDDM orthologous diabetes loci. In this event, we
envision the development of more advanced therapies that take into account the specific
iii
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IDDM alleles , transplantation tolerance alleles and HLA haplotype when a person with
type 1 diabetes is evaluated for a curative islet graft in the clinic.
i(/
Figure 13
ALTERNATE VIEW
Idd Loci
Transplantatim
Tolerance Loci
Cellular
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Legend to Figure 13: A revised schematic diagram depicting the relationship between
the genetic and cellular basis of autoimmunity and transplantation tolerance induction in
NOD mice, based on the data presented in this dissertation. This alternative view
proposes that different sets of genes contribute independently to the two phenotypes and
that the ongoing autoimmune process does not control transplantation tolerance. The
model does not exclude the possibilty, as indicated by question marks, that the gene sets
and the cellular abnormalities they cause overlap (See also Figure 2).
.; 
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